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ABSTRACT 
 The use of in vitro fertilization (IVF) has increased over the last several decades 
in the United States. The influence of IVF on pregnancy complications is not well 
understood and current methods for quantifying overall success of IVF procedures may 
be flawed. The aims of this dissertation were to evaluate the extent to which various 
aspects of IVF treatment are associated with the risk of ischemic placental disease (IPD, 
defined as preeclampsia, placental abruption, or small for gestational age infant) and to 
apply novel methods for measuring live birth after IVF success. We used data from a 
large tertiary care center and an affiliated infertility treatment center.  
In Study 1, we found an increased risk of IPD in pregnancies conceived by donor 
and autologous IVF compared with non-IVF pregnancies (risk ratio (RR): 2.5, 95% 
confidence interval (CI): 2.1-3.1 and RR 1.8, 95% CI: 1.7-2.0, respectively), and the risks 
were consistently higher for donor IVF pregnancies than autologous IVF pregnancies. In 
Study 2, we found an increased risk of IPD in pregnancies in the highest and middle 
tertiles of serum progesterone levels among autologous IVF cycles compared with the 
lowest tertile (RR 2.0, 95% CI 1.3-3.3 and RR 1.6, 95% CI 0.6-2.6, respectively), 
		 vi 
although the results were not imprecise. In study 3, we used inverse probability-of-
censoring weighting (IPCW) to address a potential violation of the uninformative 
censoring assumption of the Kaplan-Meier (KM) survival analysis to calculate the 
cumulative incidence of live birth after multiple cycles of IVF. The two approaches were 
similar (cumulative incidence of live birth 69.1% using IPCW and 73.9% using KM).  
However, additional information is needed to calculate better IPCW weights, which may 
be more important when investigating exposure/outcome relationships.   
Our results suggest that women undergoing IVF, particularly donor IVF, might 
benefit from counseling about the increased risk of IPD. Our results also suggest that 
IPCW methods offer an improvement over other methods for validly estimating 
cumulative incidence of live birth across multiple IVF cycles. The routine application of 
IPCW methods to estimating incidence of live birth in epidemiologic studies will allow 
patients to make better-informed decisions about whether to pursue treatment. 
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1.0 INTRODUCTION 
Infertility, defined as the inability to conceive after at least one year of 
unprotected intercourse1, affects up to 15% of couples in the United States (US).2 
According to the Centers for Disease Control and Prevention, approximately 6% of 
married women between 15-44 years of age are unable to conceive after one year of 
attempts and approximately 12% of similarly-aged women have difficulty conceiving and 
carrying a pregnancy to term.3  
Over the last several decades, advances have been made in assisting couples with 
conception, including treatment with medication and assisted reproductive technologies 
(ART). ART includes treatments where oocytes and embryos are handled outside of the 
body.4  
In vitro fertilization (IVF) is one type of ART where the embryo is fertilized 
outside of the body and then transferred into the uterus.5 The first successful IVF 
procedure was performed in 1978;6,7 IVF currently accounts for approximately 1-2% of 
all births in the United States.5,8 The IVF process involves four steps: 1. ovulation 
induction, when a woman is given hormones to stimulate ovulation, 2. oocyte retrieval, 3. 
oocyte insemination outside of the body after which the oocyte is allowed to fertilize and 
begin developing, and 4. embryo transfer, when the developing embryo is transferred to 
the uterus.7 There are several variations to this process. If a woman is using her own eggs 
(“autologous IVF”), then her ovulation is induced and her oocytes are collected, 
fertilized, and transferred to the uterus. If a woman is not able to use her own oocytes, 
IVF may be carried out using oocytes from a donor (“donor IVF”) in which the donor 
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undergoes ovulation induction and oocyte retrieval, and the woman with infertility, the 
recipient, undergoes the embryo transfer process. In addition, if the embryo transfer 
happens as soon as the embryo has sufficiently developed, it is considered a “fresh” IVF 
cycle. However, if the process is paused and the embryo is frozen and then thawed prior 
to transfer, this is considered a “frozen” IVF cycle.  
Although IVF has allowed many women to conceive who otherwise could not, it 
has been associated with several adverse health outcomes in the women and infants. IVF 
treatment has been associated with preeclampsia, gestational diabetes, bleeding disorders, 
preterm birth (birth prior to thirty-seven weeks of gestation), low birthweight, and small 
for gestational age (SGA) infants.9–17 In addition, IVF procedures in which multiple 
embryos are transferred have been associated with pregnancies resulting in multiple 
births, which carry their own risks to both the mother and the infants.9  
Two of these adverse outcomes, preeclampsia and SGA, along with placental 
abruption, are together known as ischemic placental disease (IPD). Preeclampsia is 
defined as de novo onset of hypertension in pregnancy after 20 weeks of gestation with 
either proteinuria or other multi-system signs of severe disease,18 placental abruption is 
the premature separation of the placenta from the uterine wall,19 and SGA is defined as 
infant birth weight below the 10th percentile, adjusted for gestational age and sex.20 
Abnormal placentation, specifically insufficient placentation, is believed to play a role in 
the etiology of IPD.10,21–23  
One hypothesis suggests that the increased risk of IPD among IVF pregnancies 
may relate to the underlying infertility as well as the IVF procedures.11,17,23–25 An 
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alternative hypothesis pertains to the maternal immunologic response to the pregnancy, 
which is also thought to influence placentation and result in obstetric and neonatal 
complications, such as IPD.10,22,26 Unlike in a spontaneously-conceived pregnancy, in a 
donor IVF cycle, a woman does not share any genetic material with the fetus, potentially 
leading to a heightened immune response and decreased maternal tolerance to the fetus. 
Another hypothesis relates to elevated serum progesterone levels on the day medications 
are given to induce the final stages of oocyte maturation in an autologous IVF cycle.7,27 
Progesterone levels at this point in the cycle should be suppressed and are allowed to rise 
after oocyte maturation. The premature elevation of progesterone may cause the 
endometrial lining to be prepared too early and reduce uterine receptivity later in the 
cycle, leading to abnormal placentation.28–30  
IVF can increase the risk for adverse outcomes among those women with a 
successful pregnancy. However, not all IVF cycles are successful. To validly test factors 
associated with IVF success, it is important to quantify the probability of live birth over 
multiple cycles. Several approaches have been used to measure success, including live 
birth rate per cycle and cumulative incidence of live birth using Kaplan-Meier survival 
analysis, but each has methodological limitations that have not been addressed.31–34 
Reporting live birth rate per IVF cycle does not account for the potential need for 
multiple cycles per woman. Using Kaplan-Meier survival analysis addresses this 
particular issue; however, survival analysis assumes uninformative censoring, meaning 
that women who drop out of treatment before achieving a live birth have the same 
average probability of a live birth as the women who remain in treatment.  
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There is evidence to suggest that women who drop out of treatment have a lower 
probability of live birth,31–33,35,36 and there is concern that the Kaplan-Meier survival 
analysis may overestimate the cumulative incidence of live birth.33,37,38   
Using data from an IVF clinic and tertiary care hospital in the Boston area, this 
dissertation will evaluate the association between donor and autologous IVF and the risk 
of IPD (paper #1), the association between premature elevated serum progesterone and 
the risk of IPD (paper #2), and the use of inverse probability-of-censoring weighting to 
address methodological issues in quantifying overall IVF success (paper #3). The results 
of these studies can be used to provide more accurate information for clinicians and 
patients about the risks of IPD and the chances for a live birth after IVF treatment. 	 	
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2.0 THE RISK OF ISCHEMIC PLACENTAL DISEASE AMONG WOMEN 
UNDERGOING DONOR AND AUTOLOGOUS IN VITRO FERTILIZATION 
 
2.1 BACKGROUND 
Ischemic placental disease (IPD), defined as preeclampsia, placental abruption, 
and/or small for gestational age (SGA), affects 16-23% of pregnancies in the United 
States.1–3 These three conditions can occur separately; however, they often co-occur and 
have shared risk factors.2,3 The etiology of IPD is not well understood, but most 
hypotheses postulate that abnormal placentation plays a critical role.4–6 Specifically, 
insufficient placentation, or failure of the trophoblasts to properly invade the placental 
bed, is believed to be the pathogenesis for IPD.6,7 IPD contributes to more than half of all 
medically-indicated deliveries before 35 weeks of gestation3  and half of all preterm 
births.7 Infants born preterm are at increased risk for many adverse outcomes, including 
infection, respiratory distress syndrome, pulmonary hypoplasia, and neurological 
complications.7 IPD can also affect the offspring, and has been associated with adult-
onset diseases, such as diabetes, metabolic syndromes, and coronary artery disease.7   
Several risk factors for IPD have been identified, including advanced maternal 
age, nulliparity, multiple gestations, chronic hypertension, diabetes, and a history of one 
of the conditions of IPD.3,6,8–10 More recently, in vitro fertilization (IVF) has been found 
to increase the risks of preeclampsia6,8,10–16 and SGA by up to 60%.13,17,18 In addition, 
IVF pregnancies have been found to have up to five times the risk of placental 
abruption8,11,12 Studies assessing differences between donor IVF, using a donated oocyte, 
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and autologous IVF, using maternal oocytes, have been mixed.6,8,14,19,20 However, the 
mechanism behind the increased risk of IPD is not clear. One hypothesis postulates that 
the increased risk of IPD may relate to underlying infertility independent of the IVF 
procedures or to the IVF procedures themselves.7,8,18,21,22 An alternative hypothesis 
pertains to the maternal immunologic response to the pregnancy, which also is thought to 
be involved in placentation.5,6,14 Maternal immune tolerance is necessary in any 
pregnancy, given the woman shares only half of the genetic material with the fetus.23 
Women who undergo donor IVF do not share any genetic material with the fetus, 
potentially decreasing the immune tolerance needed for a healthy pregnancy.6,14,23 This 
decreased maternal tolerance to the fetus may lead to a higher risk of abnormal 
placentation and result in obstetric and neonatal complications.5,6,23  
If the immunologic hypothesis is correct, we would not only expect to observe an 
elevated risk of IPD among pregnancies conceived through IVF compared with 
spontaneous pregnancies, but we would expect to observe an even higher risk of IPD for 
IVF pregnancies conceived with donor oocytes (“donor IVF”) compared with IVF 
pregnancies conceived with a woman’s own oocytes (“autologous IVF”). To assess this 
hypothesis, we evaluated the association between type of IVF (donor and autologous) and 
the risk of IPD among pregnancies 20 weeks of gestation or greater.	
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2.2 METHODS 
2.2.1 Study population 
We included all deliveries of live born infants and intrauterine fetal demise 
(IUFD) at or after 20 weeks of gestation from January 1, 2000 through June 1, 2015 at 
Beth Israel Deaconess Medical Center (BIDMC), a large tertiary care hospital. We 
identified pregnancies that resulted in an IUFD using ICD9 discharge diagnosis codes 
(656.41, 656.43, V27.1) and confirmed all IUFDs by medical record review. 
 
2.2.2 In vitro fertilization 
We evaluated three exposure groups for this analysis. “Donor IVF” was defined 
as women who underwent IVF with donor oocytes and “autologous IVF” was defined as 
women who underwent IVF with their own oocytes. Women undergoing either type of 
IVF procedure could use partner or donor sperm. Non-IVF pregnancies were the 
reference group for both IVF groups.  All IVF information, including the oocyte source 
and infertility diagnosis, was abstracted through electronic medical records at Boston 
IVF, BIDMC’s affiliated infertility treatment center.  
Although Boston IVF and BIDMC are affiliated, they maintain separate electronic 
health records and do not have a unique identifier that links IVF cycles and deliveries. 
Therefore, we used a multi-step approach to link the data to identify exposure status. We 
used maternal last name, date of birth, and time of conception to match IVF cycles and 
deliveries. First, all IVF cycles (fresh and frozen) performed at Boston IVF from January 
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1, 1999 through June 1, 2015 were identified electronically using clinic-specific 
procedure codes. We used cycles beginning in 1999 to capture pregnancies that delivered 
in 2000. Only cycles that had a confirmed clinical pregnancy were included, and IVF 
cycles that were known to end in an ectopic pregnancy, miscarriage, or therapeutic 
abortion were excluded.  
We calculated the start of the menstrual cycle from both data sources. From the 
BIDMC delivery information, the first date of the last menstrual period (LMP) was 
calculated by subtracting the gestational age at delivery from the date of delivery and this 
was used as the time of pregnancy conception. To allow for some error in gestational age 
dating, we created a window of 28 days before and 28 days after the LMP. The cycle start 
date was based on the Boston IVF data. An eight-week window was chosen in order to 
ensure that we were adequately capturing the start of the pregnancy due to differences in 
the length of an IVF cycle for each woman, while not allowing a large enough window to 
capture a second pregnancy after a potentially failed IVF cycle. Two approaches were 
used to match the data. First, matches were identified if the cycle start date fell within the 
56-day window and the maternal date of birth and last name were identical. Due to 
concerns about spelling differences of the last name between the two datasets, a second 
match was done on the remaining cycles and deliveries using only the 56-day window 
and maternal date of birth. We reviewed the matches identified using these relaxed 
criteria to confirm the match. All remaining deliveries that did not match to a Boston IVF 
cycle were considered non-IVF pregnancies. 
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2.2.3 Ischemic placental disease 
The primary outcome was IPD (the presence of preeclampsia, placental abruption, 
an SGA infant) or an IUFD where the cause was classified by the physician as being 
related to placental insufficiency. SGA is defined as a birthweight below the 10th 
percentile within strata of gestational age at delivery and infant sex. A US sample was 
used for the standard growth curve.24 In the case of multiple gestations, if any of the 
infants met criteria for SGA, the pregnancy was determined to be affected by SGA. Some 
infants who meet criteria for SGA may be constitutionally small, but healthy. To isolate a 
group of infants who are more likely to be pathologically small, we also used a 3rd 
percentile cut-off1,9 in a secondary analysis. Infant birthweight and sex was available 
electronically for all live births. For IUFDs, we abstracted the data from the medical 
record. We could not calculate SGA for all IUFDs given stillbirth weight was missing for 
170 records and infant sex was missing for 34 records, particularly those with IUFDs at 
earlier gestational ages.  
We identified potential cases of preeclampsia using ICD9 diagnosis codes 642.40-
642.44, 642.50-642.54, 642.60-642.64, 642.70-642.74, 642.51, and 642.53. Due to 
concerns about misclassification, we conducted a medical record review to verify 
preeclampsia diagnoses. Preeclampsia was defined as the presence of elevated blood 
pressure (>140/80) during the delivery admission, as well as either symptoms of 
preeclampsia (headache, visual changes, severe abdominal pain, or seizures) or abnormal 
laboratory values (proteinuria, alanine aminotransferase (ALT)/aspartate 
aminotransferase (AST)>80 units per liter, or platelets <100,000) before delivery. ICD9 
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cases not verified in the medical record were considered to not have preeclampsia. 
We identified potential cases of placental abruption using ICD9 diagnosis codes 
641.20-641.23 and also conducted a medical record review to verify the diagnosis. 
Placental abruption was defined as evidence of abruption or blood clot during a delivery; 
evidence of abruption on placental pathology; or a very strong clinical suspicion that 
required hospitalization, intervention, and delivery. ICD9 cases not verified in the 
medical record were considered to not have placental abruption. 
We reviewed autopsy, pathology, and clinician notes for documented evidence of 
placental insufficiency as a possible cause of the IUFD.   
Due to institutional changes regarding scanned paper records, data sufficient for 
validation of preeclampsia and placental abruption were only available after July 1, 2008; 
therefore, we reviewed 59.2% of preeclampsia diagnoses and 53.6% of placental 
abruption diagnoses. Among the reviewed records, we confirmed 89.3% of the potential 
preeclampsia cases and 89.7% of the potential abruption cases. We were able to confirm 
all IUFDs. AMM and two obstetricians reviewed the medical records. All diagnoses that 
were unclear were reviewed by a fellowship-trained maternal-fetal medicine physician. 
 
2.2.4 Covariates 
Demographic data and delivery outcomes were gathered electronically. Maternal 
age, race/ethnicity, marital status, and insurance were self-reported by the mother during 
hospital registration. Insurance was collapsed into public insurance (e.g. Medicaid), 
private, and self-pay or uninsured. Gravidity, parity, gestational age at delivery, mode of 
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delivery, infant sex, birth weight, and Apgar scores were recorded by a clinician at 
delivery. Gravidity and parity refer to the pregnancy being studied; therefore, all women 
were gravid. However, if this was the woman’s first pregnancy (gravidity=1), she was 
nulliparous (parity=0). One primary infertility diagnosis was recorded by the 
reproductive endocrinologist at Boston IVF before the first IVF cycle based on clinical 
opinion at the time of evaluation. 
For IUFDs, only registration and infertility diagnosis data were available 
electronically. Therefore, the remaining data were abstracted from the medical record, 
when available. Apgar scores were not assessed for IUFDs. 
 
2.2.4 Statistical analysis 
We calculated risk ratios and 95% confidence intervals using log-binomial 
regression and generalized estimating equations with an independent correlation matrix to 
account for repeated pregnancies for the same woman. Potential confounders were 
chosen based on the literature, as well as a comparison of covariates that differed by 
exposure and outcome. Maternal age at LMP as a continuous variable was included in all 
models as a covariate due to the age differences among exposure groups and because age 
is a strong risk factor for IPD. Each covariate was individually included in the regression 
model with the exposure and age. The covariate that had the strongest effect on the risk 
ratio was retained in the model and this process was repeated until no covariate changed 
the risk ratio by more than 10%. The covariates considered were race/ethnicity 
(Caucasian vs. not Caucasian), gravidity (1, 2, 3 or more), parity (0, 1, 2, 3 or more), and 
		
15 
year of delivery and they were collapsed into categories due to small sample size in some 
of the strata.  
To address limitations in the data, we conducted several sensitivity analyses. First, 
data were restricted to singleton pregnancies, because IVF pregnancies have a higher risk 
of multiple gestations and pregnancies with multiple gestations also are at higher risk for 
IPD. We were unable to determine whether women had a history of IPD, which is a 
strong predictor of future IPD; thus, a second sensitivity analysis was done restricting to 
nulliparous women. Given potential differences in the gestational age at diagnosis of the 
components of IPD, a sensitivity analysis was performed using discrete-time Cox 
proportional hazards models with gestational age at delivery as the time scale (usually 
referred to as the fetuses-at-risk model).25 Gestational age at delivery was used as a proxy 
measure because gestational age at diagnosis was not available for many records. To 
address the potential for unmeasured confounding due to differences in IVF and non-IVF 
populations, we also conducted a 1:1 nearest neighbor matched propensity score analysis. 
Propensity scores needed to be within 0.05 in order to match. Age, year of delivery, 
race/ethnicity, marital status, gravidity, parity, and insurance were included in the 
propensity score model and separate matched analyses were conducted to compare donor 
IVF to non-IVF and autologous IVF to non-IVF.  
Finally, we conducted a probabilistic quantitative bias analysis25 to quantify the 
potential effect of bias from exposure and outcome misclassification, which could arise 
when using administrative data. We conducted the bias analysis separately for donor IVF 
and autologous IVF groups, using the non-IVF group as a common reference group. We 
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used IPD or IUFD with placental insufficiency as the outcome. We assumed non-
differential misclassification for the exposure and the outcome; each simulation was run 
10,000 times. We used several considerations in our choice of sensitivity and specificity 
for the bias correction. Boston IVF performs approximately one-third of IVF cycles in the 
Greater Boston area.26 For exposure misclassification, we used a trapezoidal sensitivity 
distribution (minimum sensitivity 35%, modes at 50% and 70%, maximum 80%). These 
values were chosen because, due to the affiliation between Boston IVF and BIDMC, we 
believe that the majority of IVF deliveries at BIDMC would be from cycles performed at 
Boston IVF. We assumed 100% specificity for exposure because IVF pregnancies are 
unlikely to be misclassified as non-IVF pregnancies. For our outcome misclassification, 
we also used a trapezoidal distribution for sensitivity (minimum 60%, modes at 70% and 
75%, maximum 80%) and a triangular distribution for specificity (minimum 80%, mode 
90%, maximum 95%) based on our medical record review. 
  
2.3 RESULTS 
2.3.1 Baseline demographics 
We identified 69,745 pregnancies. Of these, 206 (0.3%) were in the donor IVF 
group and 2,132 (3.1%) were in the autologous IVF group. The minimum maternal age 
was 21.8 years in the donor IVF group, 23.5 years in the autologous IVF group, and 13.2 
years in the non-IVF group. Due to concerns about residual confounding due to 
differences in age, anyone less than 21.8 years of age was excluded. Demographic and 
baseline characteristics for the three exposure groups are presented in Table 2.1. The 
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three groups differed on several demographic characteristics that are important risk 
factors for IPD. Women in the donor IVF group were the oldest and those in the non-IVF 
group were the youngest (Table 2.1). In addition, women in the non-IVF group were less 
likely to be primigravid and nulliparous than their IVF counterparts. Almost all women in 
both IVF groups had private insurance coverage compared with 86.0% of the non-IVF 
group. Within the two IVF groups, there were some differences in the primary infertility 
diagnosis. The most common diagnosis in the donor IVF group was diminished ovarian 
reserve and the most common diagnosis in the autologous IVF group was unexplained 
infertility.  
 
2.3.2 Delivery outcomes 
The median gestational age at delivery was similar across the three exposure 
groups: 38.0 weeks in the IVF groups and 39.0 weeks in the non-IVF group. Both IVF 
groups had a higher incidence of preterm delivery (32.5% in the donor group and 31.2% 
in the autologous group) than the non-IVF group (11.1%) and multiple gestations also 
were more common in both IVF groups (37.4% in the donor IVF group and 31.4% in the 
autologous group) compared with the non-IVF group (2.9%). IUFDs were rare in this 
cohort, and there were no differences in the risk of IUFD among the three groups. In 
addition, there were no differences in neonatal outcomes (Table 2.2). 
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2.3.3 Incidence and risk of ischemic placental disease 
Overall, 14.0% of the cohort had IPD. More than one-third (35.9%) of the donor 
IVF group and one-quarter (26.6%) of the autologous IVF group had IPD compared with 
13.5% in the non-IVF group. When adjusted for maternal age and parity, compared with 
the non-IVF group, the risk of IPD was 2.5 (95% CI: 2.1-3.1) in the donor IVF group and 
1.8 (95% CI: 1.7-2.0) in the autologous IVF group. The risks of each of the components 
of IPD were higher in the donor IVF and autologous IVF groups compared with the non-
IVF group (Table 2.3).  When restricting the definition of SGA to <3rd percentile and 
adjusting for maternal age and parity, the risk of IPD was higher among those undergoing 
donor IVF (RR 3.2, 95% CI: 2.5-4.0) and autologous IVF (RR 2.0, 95% CI: 1.8-2.2) 
compared with the non-IVF group. Similar results were seen when comparing the risk of 
SGA <3rd percentile.  
Women undergoing donor IVF had a higher risk of IPD compared with women 
undergoing autologous IVF (RR 1.4, 95% CI: 1.1-1.8) and preeclampsia (RR 2.8, 95% 
CI: 2.0-4.0) when adjusted for maternal age (Table 2.4). When restricting the definition 
of SGA to <3rd percentile, the donor IVF group had a higher risk of IPD compared with 
the autologous group (RR 1.8, 95% CI: 1.4-2.4) when adjusted for maternal age. 
 
2.3.4 Sensitivity analyses 
Baseline demographic characteristics and delivery outcomes were similar when 
restricting to singleton pregnancies. (Table 2.5 and Table 2.6). The risk of IPD was 
similar in the singleton cohort (RR 2.1, 95% CI: 1.6-2.9 in the donor IVF group and RR 
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1.2, 95% CI 1.0-1.3 in the autologous IVF group, adjusted for maternal age and 
gravidity) compared with the entire cohort. However, the risk of SGA was attenuated and 
the risk of abruption was higher. In addition, when we restricted the definition of SGA to 
<3rd percentile, the risk of IPD in the autologous IVF group was attenuated and we no 
longer saw an association between method of conception and the SGA <3rd percentile 
component among the singleton pregnancies (Table 2.7). 
Demographic characteristics and delivery outcomes among the three groups were 
similar when restricted to nulliparous women except that the non-IVF group was more 
likely to be primigravid than the donor IVF group. (Table 2.8 and Table 2.9). The risk of 
IPD was similar to the entire cohort (RR 2.3, 95% CI: 2.0-3.0 in the donor group and RR 
1.7, 95% CI: 1.6-1.9 in the autologous group, adjusted for maternal age). (Table 2.10).   
Gestational age at delivery did not differ by mode of conception but the hazard 
ratios showed a stronger relationship between mode of conception and IPD. The donor 
IVF group had 3.6 times the hazard of IPD (95% CI: 2.9-4.6, adjusted for maternal age 
and parity) compared with the non-IVF group, and the autologous group had 2.6 times 
the hazard of IPD (95% CI: 2.4-2.8, adjusted for maternal age and parity) compared with 
the non-IVF group (Table 2.11). 
There was good overlap in the distribution of propensity scores for both matched 
analyses (Figures 2.1 and 2.2). The sample size for the donor IVF analysis was small, and 
women in the donor IVF group were more likely to be Caucasian than women in the non-
IVF group. The rest of the demographic characteristics were similar (Table 2.12). 
Women in the donor IVF group were 1.7 times as likely to have IPD compared with 
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women in the non-IVF group (95% CI: 1.2-2.4), which was a lower risk than we 
observed in the entire cohort (Table 2.13). The risks for preeclampsia and placental 
abruption were higher in the matched analysis compared with the entire cohort; however, 
the confidence intervals were wide. The matched analysis comparing autologous IVF and 
non-IVF had a larger sample size and better balance of demographic factors (Table 2.14). 
Women in the autologous IVF group had 1.7 times the IPD risk of women in the non-IVF 
group (95% CI: 1.5-2.0), which was similar to the entire cohort. (Table 2.15). The risks 
of the components of IPD in the autologous IVF group also were similar to the risks seen 
in the entire cohort. 
The quantitative bias analysis showed that there was little error in our estimate 
when correcting for exposure misclassification (corrected RR 2.60 for donor IVF 
compared with non-IVF and corrected RR 1.97 for autologous IVF compared with non-
IVF). Correcting for outcome misclassification showed a stronger relationship between 
donor IVF and IPD (corrected RR 7.88) and autologous IVF and IPD (corrected RR 4.95, 
Table 2.16). 
 
2.4 DISCUSSION 
In the present study, women who conceived with IVF were at higher risk of IPD 
compared with women who conceived without IVF. In particular, compared with the 
non-IVF group, women who conceived using donor IVF were almost three times more 
likely to develop IPD and women who conceived using autologous IVF had double the 
risk of IPD. These findings persisted when we evaluated the components of IPD 
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(preeclampsia, placental abruption, and SGA) separately. Furthermore, when restricting 
the definition of SGA to <3rd percentile, thereby substantially reducing the proportion of 
constitutionally small babies from the IPD definition, the relationship between method of 
conception and IPD became stronger. Women undergoing donor IVF also had a higher 
risk of IPD compared with the autologous IVF group. Our results were robust to multiple 
sensitivity analyses, including restricting the cohort to singleton gestations and 
nulliparous women. In addition, we found stronger associations when we accounted for 
gestational age at delivery using the discrete-time Cox proportional hazards model. The 
matched propensity score analysis also showed similar results, although some of the 
results in the donor IVF comparison were attenuated. 
We did see some attenuated risks for SGA when restricting to singleton 
pregnancies, particularly when using a more stringent definition of SGA (<3rd percentile). 
This may be because women with a singleton pregnancy are at lower risk SGA. In 
addition, restricting the analysis to singleton pregnancies may impose a bias. IVF, 
particularly the number of embryos transferred during the procedure, has been associated 
with an increased risk of multiple gestations, which are at higher risk for SGA, and we 
are conditioning on a variable on the causal pathway between our exposure and outcome.  
Our results are consistent with prior literature that shows an increased risk of IPD 
in IVF pregnancies, as well as an increased risk of preeclampsia in donor IVF 
pregnancies.6,14,16,19,20,27 In this study, we were able to evaluate the association between 
type of IVF and risk of IPD as a group of biologically related conditions. Our results 
support the hypothesis that there are multiple mechanisms contributing to the higher risk 
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of IPD. Given both donor and autologous IVF pregnancies had a higher risk of IPD, this 
lends support to the theory that there is a role for infertility or IVF treatment. In addition, 
the higher risk in the donor IVF group potentially indicates that a second mechanism, 
such as the heightened maternal immune response to the fetus, may also contribute.  
This study has several limitations. Due to our reliance on electronic medical 
records, we did not have data on important potential confounders such as body mass 
index, maternal diabetes, prior IPD, infertility among the non-IVF group, other infertility 
treatments, smoking, and other medical history. We conducted a sensitivity analysis 
restricting our cohort to nulliparous women to evaluate the effect of IPD in a prior 
pregnancy and our results were similar; however, we were unable to evaluate the effect of 
obesity and diabetes on the results. Lack of control for obesity and diabetes, which are 
positively associated with IVF and IPD, may have led to an overestimation of the RR. 
Furthermore, there may be differences in BMI and diabetes between the two IVF groups, 
which may also lead to an overestimation of the RR between the donor and autologous 
IVF groups. Our inability to control for infertility and other infertility treatments in our 
non-IVF group would not likely explain our results. Infertility and infertility treatment is 
expected to increase the risk of IPD, thereby biasing our estimates towards the null. 
The use of electronic medical records and billing data introduces potential for 
misclassification in the exposure and the outcome. It is likely that there are women in our 
non-IVF group who did undergo IVF, as we are unable to identify women in the non-IVF 
group who underwent IVF at a center other than Boston IVF. However, we do not have 
any reason to believe that IPD risk would differ by infertility treatment center and we 
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expect the exposure misclassification to be non-differential. A probabilistic quantitative 
bias analysis showed almost no effect of exposure misclassification on our association, 
even with a low sensitivity of exposure classification. This is likely due to the large 
unexposed population in this study. Our use of ICD9 codes may have allowed for 
misclassification of our outcome as well. We were able to confirm more than half of the 
ICD9 codes but were limited in available medical records. The ICD9 codes had high 
positive predictive value (89.4% for preeclampsia and 89.7% for placental abruption); 
however, some women classified as having preeclampsia or placental abruption may not 
have been true cases. Conversely, women with preeclampsia or placental abruption may 
not have received the correct ICD9 code. We would anticipate the outcome 
misclassification to be non-differential with respect to exposure and to attenuate our 
results given that the medical management for these conditions would not differ by IVF 
procedure. Our probabilistic quantitative bias analysis showed that the risk of IPD, 
corrected for non-differential outcome misclassification, would be notably stronger than 
the risks we observed.  
Another limitation is that we used published singleton growth curves to calculate 
SGA for both singletons and multiples. Since multiples are generally smaller at all 
gestational ages, this could have led to an over-diagnosis of SGA in the multiples. 
However, our sensitivity analysis restricting to singletons showed similar overall results, 
as noted above.  
It is generally difficult to determine the exact cause of an IUFD or the exact 
timing of the IUFD. While we were able to review available autopsy, placental 
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pathology, and other clinical documentation, it is likely that some of the IUFDs attributed 
to placental insufficiency were incorrectly classified. In addition, IUFDs caused by 
placental insufficiency may have been missed. However, due to the overall small 
numbers of IUFDs in this study, we would expect the effect of this misclassification to be 
minimal. 
Another limitation was our use of data from one institution, thereby limiting 
generalizability of the results. However, the demographic characteristics of the IVF 
groups in our study are representative of IVF populations in other studies and the 
differences between the IVF and non-IVF groups that we saw were expected. In addition, 
the overall incidence of preeclampsia, placental abruption and SGA in our population 
was similar to what has been reported previously.  
Finally, we were only able to assess the association between IVF and IPD among 
pregnancies that were 20 weeks of gestation or greater. We do not know about the risk of 
IPD among pregnancies that did not survive to 20 weeks. In order for this to explain the 
results from this study, the risk of IPD would need to be greater among pregnancies lost 
in the non-IVF group. It is more likely that the risk of IPD would be greater among 
pregnancies lost in the IVF groups, biasing our estimate towards the null.  
Strengths of the study include the large sample size and the use of both IVF and 
obstetrical records. This allowed us to examine the individual components of IPD, adjust 
for several confounders, and conduct multiple sensitivity analyses. In addition, exposure, 
outcome, and covariate data were recorded prospectively in medical records and there 
was no need to rely on physician recall or maternal report. The use of a composite 
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outcome comprised of four individual pregnancy complications that share a common set 
of risk factors can help clarify causal mechanisms.  
 
2.5 CONCLUSION  
The present study found pregnancies conceived via donor IVF or autologous IVF 
had a higher risk of IPD than non-IVF pregnancies. This was particularly the case for 
preeclampsia and SGA when restricted to <3rd percentile. Associations were consistently 
stronger for donor IVF than autologous IVF. Our results suggest that women undergoing 
IVF should be counseled about these risks and increased maternal/fetal surveillance may 
be considered. 	  
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2.6 TABLES 
Table 2.1: Baseline patient characteristics of deliveries from January 1, 2000 
through June 1, 2015 by mode of conception (n=66,452) 
 Donor IVF 
(n=206) 
Autologous IVF 
(n=2132) 
Non-IVF 
(n=64114) 
Demographic characteristics    
Maternal age (years) 42.2 (39.2-45.0) 35.8 (32.9-38.9) 32.2 (29.2-35.2) 
Race    
Caucasian 168 (81.6) 1667 (78.2) 37600 (58.6) 
African American 11 (5.3) 77 (3.6) 6456 (10.1) 
Hispanic 1 (0.5) 36 (1.7) 3077 (4.8) 
Asian 6 (2.9) 132 (6.2) 8847 (13.8) 
Other 9 (4.4) 82 (3.8) 2869 (4.5) 
Not reported/unknown 11 (5.3) 138 (6.5) 5265 (8.2) 
Marital status    
Married or partnered 181 (87.9) 1980 (93.0) 52101 (81.3) 
Single 21 (10.2) 100 (4.7) 9348 (14.6) 
Divorced, separated or 
widowed 
2 (1.0) 18 (0.8) 725 (1.1) 
Unknown/missing 2 (1.0) 34 (1.6) 1940 (3.0) 
Gravidity    
1 130 (63.1) 1442 (67.6) 22820 (35.6) 
2 42 (20.4) 349 (16.4) 20639 (32.2) 
3+ 33 (16.0) 339 (15.9) 20608 (32.1) 
Missing 1 (0.5) 2 (0.1) 47 (0.1) 
Parity    
0 131 (63.6) 1399 (65.6) 29359 (45.8) 
1 57 (27.7) 629 (29.5) 23372 (36.5) 
2 15 (7.3) 84 (3.9) 8226 (12.8) 
3+ 3 (1.5) 20 (0.9) 3114 (4.9) 
Missing 0 (0.0) 0 (0.0) 44 (0.1) 
Insurance    
Public  2 (1.0) 20 (0.9) 8783 (13.7) 
Private, other 204 (99.0) 2111 (99.0) 55136 (86.0) 
Uninsured 0 (0.0) 1 (0.1) 195 (0.3) 
Primary infertility diagnosis    
Diminished ovarian 
reserve 
69 (33.5) 138 (6.5) - 
Ovarian dysfunction 14 (6.8) 201 (9.4) - 
Tubal factor 1 (0.5) 159 (7.5) - 
Endometriosis 0 (0.0) 88 (4.1) - 
Uterine factor 0 (0.0) 49 (2.3) - 
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Male factor 9 (4.4) 454 (21.3) - 
Other 68 (33.1) 151 (7.1) - 
Unexplained 13 (6.3) 741 (34.8) - 
Missing 32 (15.5) 151 (7.1) - 
IVF: In vitro fertilization 
Data presented as median (interquartile range) or n (%) 
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Table 2.2: Immediate pregnancy and delivery outcomes of cohort by mode of 
conception (n=66,452) 
Outcomes Donor IVF 
(n=206) 
Autologous IVF 
(n=2132) 
Non-IVF 
(n=64114) 
Gestational age at delivery 
(weeks) 38.0 (36.0-39.0) 38.0 (36.0-39.0) 39.0 (38.0-40.0) 
Preterm delivery (<37 weeks 
of gestation) 67 (32.5) 666 (31.2) 7146 (11.1) 
Intrauterine fetal demise 
(IUFD) 0 (0.0) 6 (0.3) 280 (0.4) 
Mode of delivery    
Vaginal  40 (19.4) 776 (36.4) 39612 (61.8) 
Cesarean 157 (76.2) 1245 (58.4) 23997 (37.4) 
Vaginal and cesarean† 9 (4.4) 109 (5.1) 425 (0.7) 
Dilation and evacuation¥ 0 (0.0) 0 (0.0) 36 (0.1) 
Missing 0 (0.0) 2 (0.1) 44 (0.1) 
Gestations    
Singleton 129 (62.6) 1463 (68.6) 62275 (97.1) 
Multiple 77 (37.4) 669 (31.4) 1839 (2.9) 
Singletons n=129 n=1463 n=62275 
Sex    
Female 65 (50.4) 735 (50.2) 30369 (48.8) 
Male 64 (49.6) 728 (49.8) 31879 (51.2) 
Unknown 0 (0.0) 0 (0.0) 27 (0.04) 
Birthweight (grams) 3240 (2865-3620) 3290 (2930-3610) 3360 (3030-3685) 
Apgar 1 minute€ 8.0 (8.0-9.0) 8.0 (8.0-9.0) 9.0 (8.0-9.0) 
Apgar 5 minutes€ 9.0 (9.0-9.0) 9.0 (9.0-9.0) 9.0 (9.0-9.0) 
Multiples* n=77 n=669 n=1839 
Sex    
Female 20 (26.0) 148 (22.1) 596 (32.4) 
Male 20 (26.0) 174 (26.0) 575 (31.3) 
Both 37 (48.1) 346 (51.7) 668 (36.3) 
Unknown 0 (0.0) 1 (0.1) 0 (0.0) 
Birthweight (grams) 2463 (1980-2855) 2327 (1847-2724) 2298 (1810-2650) 
Apgar 1 minute€ 8.0 (7.5-8.5) 8.0 (7.0-8.5) 8.0 (7.0-8.5) 
Apgar 5 minutes€ 9.0 (8.5-9.0) 9.0 (8.0-9.0) 9.0 (8.0-9.0) 
IVF: In vitro fertilization 
Data presented as median (interquartile range) or n (%) 
† Women who had multiples could deliver the infants both vaginally and via cesarean 
¥ For IUFDs only 
€ For live births only 
* Birthweights and Apgar scores combined for all infants		 	
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Table 2.3: Risk ratios for ischemic placental disease and ischemic placental disease 
components in donor in vitro fertilization (IVF) and autologous IVF groups 
compared with non-IVF group  
 
 Donor IVF 
(n=206) 
Autologous IVF 
(n=2132) 
Non-IVF 
(n=64114) 
Small for gestational age <10th percentile 
Ischemic placental disease or 
IUFD 
74 (35.9) 568 (26.6) 8647 (13.5) 
Crude RR (95% CI) 2.7 (2.2-3.2) 2.0 (1.8-2.1) 1.0 (Reference) 
Adjusted RR (95% CI)a 2.5 (2.1-3.1) 1.8 (1.7-2.0) 1.0 (Reference) 
Preeclampsia 39 (18.9) 180 (8.4) 2358 (3.7) 
Crude RR (95% CI) 5.1 (3.9-6.9) 2.3 (2.0-2.7) 1.0 (Reference) 
Adjusted RR (95% CI)a 4.0 (2.9-5.3) 1.9 (1.6-2.2) 1.0 (Reference) 
Placental abruption 9 (4.4) 69 (3.2) 839 (1.3) 
Crude RR (95% CI) 3.3 (1.8-6.4) 2.5 (1.9-3.2) 1.0 (Reference) 
Adjusted RR (95% CI)b 3.1 (1.6-6.0) 2.4 (1.9-3.1) 1.0 (Reference) 
Small for gestational age 45 (21.8) 398 (18.7) 6091 (9.5) 
Crude RR (95% CI) 2.3 (1.8-3.0) 2.0 (1.8-2.2) 1.0 (Reference) 
Adjusted RR (95% CI)a 2.4 (1.8-3.1) 1.9 (1.7-2.1) 1.0 (Reference) 
Small for gestational age <3rd percentile 
Ischemic placental disease or 
IUFD 
55 (26.7) 342 (16.0) 4435 (6.9) 
Crude RR (95% CI) 3.9 (3.1-4.9) 2.3 (2.1-2.6) 1.0 (Reference) 
Adjusted RR (95% CI)a 3.2 (2.5-4.0) 2.0 (1.8-2.2) 1.0 (Reference) 
Small for gestational age 12 (5.8) 118 (5.5) 1418 (2.2) 
Crude RR (95% CI) 2.6 (1.5-4.6) 2.5 (2.1-3.0) 1.0 (Reference) 
Adjusted RR (95% CI)a 2.6 (1.5-4.6) 2.4 (2.0-2.9) 1.0 (Reference) 
IVF: In vitro fertilization; IUFD: intrauterine fetal demise 
Data presented as n (%) or risk ratio (RR) and 95% confidence interval (CI) 
a Adjusted for age, parity 
b Adjusted for age 
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Table 2.4: Risk ratios for ischemic placental disease and ischemic placental disease 
components in donor in vitro fertilization (IVF) group compared with autologous 
IVF group 
 Donor IVF 
(n=206) 
Autologous IVF 
(n=2132) 
Small for gestational age <10th percentile 
Ischemic placental disease or 
IUFD 
74 (35.9) 568 (26.6) 
Crude RR (95% CI) 1.3 (1.1-1.6) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.4 (1.1-1.8) 1.0 (Reference) 
Preeclampsia 39 (18.9) 180 (8.4) 
Crude RR (95% CI) 2.2 (1.6-3.1) 1.0 (Reference) 
Adjusted RR (95% CI)* 2.8 (2.0-4.0) 1.0 (Reference) 
Placental abruption 9 (4.4) 69 (3.2) 
Crude RR (95% CI) 1.3 (0.7-2.7) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.3 (0.6-2.8) 1.0 (Reference) 
Small for gestational age 45 (21.8) 398 (18.7) 
Crude RR (95% CI) 1.2 (0.9-1.5) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.2 (0.9-1.6) 1.0 (Reference) 
Small for gestational age <3rd percentile 
Ischemic placental disease or 
IUFD 
55 (26.7) 342 (16.0) 
Crude RR (95% CI) 1.7 (1.3-2.1) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.8 (1.4-2.4) 1.0 (Reference) 
Small for gestational age 12 (5.8) 118 (5.5) 
Crude RR (95% CI) 1.1 (0.6-1.9) 1.0 (Reference) 
Adjusted RR (95% CI)* 0.9 (0.5-1.8) 1.0 (Reference) 
IVF: In vitro fertilization; IUFD: Intrauterine fetal demise 
Data presented as n (%) or risk ratio (RR) and 95% confidence interval (CI) 
* Adjusted for age 		 	
		
31 
Table 2.5: Baseline patient characteristics of all singleton deliveries from January 1, 
2000 through June 1, 2015 by mode of conception (n=63,867) 
 Donor IVF 
(n=129) 
Autologous IVF 
(n=1463) 
Non-IVF 
(n=62275) 
Demographic characteristics    
Maternal age (years) 42.7 (39.4-45.1) 36.2 (33.4-39.2) 32.1 (29.1-35.2) 
Race    
Caucasian 106 (82.2) 1146 (78.3) 36315 (58.3) 
African American 6 (4.7) 47 (3.2) 6315 (10.1) 
Hispanic 1 (0.8) 26 (1.8) 3006 (4.8) 
Asian 6 (4.7) 99 (6.7) 8735 (14.0) 
Other 4 (3.1) 58 (4.0) 2781 (4.5) 
Not reported/unknown 6 (4.7) 87 (5.9) 5123 (8.2) 
Marital status    
Married or partnered 113 (87.6) 1361 (93.0) 50568 (81.2) 
Single 14 (10.9) 71 (4.9) 9115 (14.6) 
Divorced, separated, widowed 2 (1.6) 9 (0.6) 709 (1.1) 
Unknown/missing 0 (0.0) 22 (1.5) 1883 (3.0) 
Gravidity    
1 79 (61.2) 971 (66.4) 22106 (35.5) 
2 25 (19.4) 249 (17.0) 20119 (32.3) 
3+ 24 (18.6) 241 (16.5) 20004 (32.1) 
Missing 1 (0.8) 2 (0.1) 46 (0.1) 
Parity    
0 81 (62.8) 911 (62.3) 28368 (45.6) 
1 36 (27.9) 470 (32.1) 22788 (36.6) 
2 10 (7.8) 67 (4.6) 8041 (12.9) 
3+ 2 (1.6) 15 (1.0) 3036 (4.9) 
Missing 0 (0.0) 0 (0.0) 42 (0.1) 
Insurance    
Public  1 (0.8) 15 (1.0) 8618 (13.8) 
Private, other 128 (99.2) 1447 (98.9) 53465 (85.9) 
Uninsured 0 (0.0) 1 (0.1) 192 (0.3) 
Primary infertility diagnosis    
Diminished ovarian reserve 46 (35.7) 106 (7.2) - 
Ovarian dysfunction 11 (8.5) 135 (9.2) - 
Tubal factor 1 (0.8) 104 (7.1) - 
Endometriosis 0 (0.0) 58 (4.0) - 
Uterine factor 0 (0.0) 38 (2.6) - 
Male factor 5 (3.9) 323 (22.1) - 
Other 42 (32.6) 110 (7.5) - 
Unexplained 6 (4.7) 480 (32.8) - 
Missing 18 (14.0) 109 (7.4) - 
IVF: In vitro fertilization 
Data presented as median (interquartile range) or n (%) 
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Table 2.6: Immediate pregnancy and delivery outcomes of singletons only by mode 
of conception (n=63,867) 
Outcomes Donor IVF 
(n=129) 
Autologous IVF 
(n=1472) 
Non-IVF 
(n=62275) 
Gestational age at 
delivery (weeks) 
39.0 (38.0-40.0) 39.0 (38.0-40.0) 39.0 (38.0-40.0) 
Preterm delivery (<37 
weeks of gestation) 
22 (17.1) 211 (14.4) 5862 (9.4) 
Intrauterine fetal 
demise (IUFD) 
0 (0.0) 4 (0.3) 267 (0.4) 
Mode of delivery    
Vaginal  40 (31.0) 773 (52.8) 39601 (63.6) 
Cesarean  89 (69.0) 688 (47.0) 22597 (36.3) 
Dilation and 
evacuation¥ 
0 (0.0) 0 (0.0) 34 (0.1) 
Missing 0 (0.0) 2 (0.1) 43 (0.1) 
Infant    
Sex    
Female 65 (50.4) 735 (50.2) 30369 (48.8) 
Male 64 (49.6) 728 (49.8) 31879 (51.2) 
Unknown 0 (0.0) 0 (0.0) 22 (0.04) 
Birthweight (grams) 3240 (2865-3620) 3290 (2930-3610) 3360 (3030-3685) 
Apgar 1 minute€ 8.0 (8.0-9.0) 8.0 (8.0-9.0) 9.0 (8.0-9.0) 
Apgar 5 minutes€ 9.0 (9.0-9.0) 9.0 (9.0-9.0) 9.0 (9.0-9.0) 
IVF: In vitro fertilization; 
Data presented as median (interquartile range) or n (%) 
¥ For IUFDs only 
€ For live births only 
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Table 2.7: Risk ratios for ischemic placental disease and ischemic placental disease 
components in donor and autologous in vitro fertilization (IVF) groups compared 
with non-IVF group, among singleton pregnancies  
 
 Donor IVF 
(n=129) 
Autologous IVF 
(n=1463) 
Non-IVF 
(n=62275) 
Small for gestational age <10th percentile 
Ischemic placental disease or 
IUFD 
34 (26.4) 221 (15.1) 7708 (12.4) 
Crude RR (95% CI) 2.1 (1.6-2.8) 1.2 (1.1-1.4) 1.0 (Reference) 
Adjusted RR (95% CI)a 2.1 (1.6-2.9) 1.2 (1.0-1.3) 1.0 (Reference) 
Preeclampsia 19 (14.7) 67 (4.6) 2065 (3.3) 
Crude RR (95% CI) 4.4 (2.9-6.7) 1.4 (1.1-1.8) 1.0 (Reference) 
Adjusted RR (95% CI)b 3.2 (2.1-5.0) 1.1 (0.9-1.5) 1.0 (Reference) 
Placental abruption 8 (6.2) 40 (2.7) 797 (1.3) 
Crude RR (95% CI) 4.8 (2.5-9.5) 2.1 (1.6-2.9) 1.0 (Reference) 
Adjusted RR (95% CI)c 4.7 (2.3-9.4) 2.1 (1.5-2.9) 1.0 (Reference) 
Small for gestational age 18 (14.0) 138 (9.4) 5357 (8.6) 
Crude RR (95% CI) 1.6 (1.1-2.5) 1.1 (0.9-1.3) 1.0 (Reference) 
Adjusted RR (95% CI)a 1.8 (1.1-2.8) 1.1 (0.9-1.3) 1.0 (Reference) 
Small for gestational age <3rd percentile 
Ischemic placental disease or 
IUFD 
26 (20.2) 132 (9.0) 3927 (6.3) 
Crude RR (95% CI) 3.2 (2.3-4.4) 1.4 (1.2-1.7) 1.0 (Reference) 
Adjusted RR (95% CI)b 2.8 (1.9-3.9) 1.3 (1.1-1.5) 1.0 (Reference) 
Small for gestational age 1 (0.8) 31 (2.1) 1206 (1.9) 
Crude RR (95% CI) 0.4 (0.1-2.8) 1.1 (0.8-1.6) 1.0 (Reference) 
Adjusted RR (95% CI)a 0.5 (0.1-3.2) 1.1 (0.8-1.5) 1.0 (Reference) 
IVF: In vitro fertilization; IUFD: Intrauterine fetal demise 
Data presented as n (%) or risk ratio (RR) and 95% confidence interval (CI) 
a Adjusted for age and gravidity 
b Adjusted for age and parity 
c Adjusted for age 	  
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Table 2.8: Baseline patient characteristics of all nulliparous deliveries between 
January 1, 2000 and June 1, 2015 by mode of conception (n=30,889) 
 Donor IVF 
(n=131) 
Autologous IVF 
(n=1399) 
Non-IVF 
(n=29359) 
Demographic characteristics    
Maternal age (years) 42.1 (39.2-44.3) 35.1 (32.2-38.4) 30.9 (28.2-33.8) 
Race    
Caucasian 104 (79.4) 1073 (76.7) 17407 (59.3) 
African American 8 (6.1) 53 (3.8) 2100 (7.2) 
Hispanic 1 (0.8) 26 (1.9) 1120 (3.8) 
Asian 4 (3.1) 94 (6.7) 4299 (14.6) 
Other 5 (3.8) 53 (3.8) 1492 (5.1) 
Not reported/unknown 9 (6.9) 100 (7.1) 2941 (10.0) 
Marital status    
Married or partnered 115 (87.8) 1277 (91.3) 23449 (79.9) 
Single 14 (10.7) 80 (5.8) 4471 (15.2) 
Divorced, separated or 
widowed 
1 (0.8) 13 (0.9) 234 (0.8) 
Unknown/missing 1 (0.8) 29 (2.1) 1205 (4.1) 
Gravidity    
1 100 (76.3) 1126 (80.5) 22727 (77.4) 
2 22 (16.8) 166 (11.9) 4408 (15.0) 
3+ 8 (6.1) 106 (7.6) 2223 (7.6) 
Missing 1 (0.8) 1 (0.1) 1 (0.0) 
Insurance    
Public  1 (0.8) 15 (1.1) 3251 (11.1) 
Private, other 130 (99.2) 1384 (98.9) 26041 (88.7) 
Uninsured 0 (0.0) 0 (0.0) 67 (0.2) 
Primary infertility diagnosis    
Diminished ovarian reserve 42 (32.1) 82 (5.9) - 
Ovarian dysfunction 10 (7.6) 129 (9.2) - 
Tubal factor 0 (0.0) 102 (7.3) - 
Endometriosis 0 (0.0) 61 (4.4) - 
Uterine factor 0 (0.0) 37 (2.6) - 
Male factor 7 (5.3) 298 (21.3) - 
Other 49 (37.4) 90 (6.4) - 
Unexplained 9 (6.9) 509 (36.4) - 
Missing 14 (10.7) 91 (6.5) - 
IVF: In vitro fertilization 
Data presented as median (interquartile range) or n (%) 	  
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Table 2.9: Immediate pregnancy and delivery outcomes of nulliparous women only 
by mode of conception (n=30,889) 
Outcomes Donor IVF 
(n=131) 
Autologous IVF 
(n=1399) 
Non-IVF 
(n=29359) 
Gestational age at 
delivery (weeks) 38.0 (35.6-39.0) 38.0 (36.0-39.0) 39.0 (38.0-40.0) 
Preterm delivery (<37 
weeks of gestational age) 46 (35.1) 473 (33.8) 3596 (12.2) 
Intrauterine fetal demise 
(IUFD) 0 (0.0) 4 (0.3) 127 (0.4) 
Gestations    
Singleton 81 (61.8) 911 (65.1) 28368 (96.6) 
Multiple 50 (38.2) 488 (34.9) 991 (3.4) 
Mode of delivery    
Vaginal  17 (13. 0) 468 (33.5) 17137 (58.4) 
Cesarean  110 (84.0) 860 (61.5) 11995 (40.9) 
Vaginal and cesarean 
delivery† 
4 (3.1) 69 (4.9) 204 (0.7) 
Dilation and 
evacuation¥ 
0 (0.0) 0 (0.0) 16 (0.1) 
Missing 0 (0.0) 2 (0.1) 7 (0.02) 
Singletons n=81 n=911 n=28368 
Sex    
Female 41 (50.6) 439 (48.2) 13766 (48.5) 
Male 40 (49.4) 472 (51.8) 14591 (51.4) 
Unknown 0 (0.0) 0 (0.0) 11 (0.04) 
Birthweight (grams) 3240 (2865-3695) 3250 (2920-3585) 3320 (2985-3645) 
Apgar 1 minute€ 8.0 (8.0-9.0) 8.0 (8.0-9.0) 8.0 (8.0-9.0) 
Apgar 5 minutes€ 9.0 (9.0-9.0) 9.0 (9.0-9.0) 9.0 (9.0-9.0) 
Multiples* n=50 n=488 n=991 
Sex    
Female 12 (30.0) 107 (21.9) 314 (31.7) 
Male 11 (22.0) 123 (25.2) 302 (30.5) 
Both 24 (48.0) 257 (52.7) 375 (37.8) 
Unknown 0 (0.0) 1 (0.2) 0 (0.0) 
Birthweight  2353 (1968-2820) 2250 (1708-2690) 2200 (1660-2580) 
Apgar 1 minute€ 8.0 (7.0-8.5) 8.0 (7.0-8.5) 8.0 (7.0-8.5) 
Apgar 5 minutes€ 9.0 (8.5-9.0) 9.0 (8.0-9.0) 8.5 (8.0-9.0) 
IVF: In vitro fertilization 
Data presented as median (interquartile range) or n (%) 
† Women who had multiples could deliver the infants both vaginally and via cesarean 
¥ For IUFDs only 
€ For live births only 
* Birthweights and Apgar scores combined for all babies	  
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Table 2.10: Risk ratios for ischemic placental disease and ischemic placental disease 
components in donor and autologous in vitro fertilization (IVF) groups compared 
with non-IVF group, among nulliparous pregnancies 
 Donor IVF 
(n=131) 
Autologous IVF 
(n=1399) 
Non-IVF 
(n=29359) 
Small for gestational age <10th percentile 
Ischemic placental disease or 
IUFD 55 (41.2) 419 (29.9) 4963 (16.9) 
Crude RR (95% CI) 2.5 (2.0-3.0) 1.8 (1.6-1.9) 1.0 (Reference) 
Adjusted RR (95% CI)a 2.3 (1.8-2.8) 1.7 (1.6-1.9) 1.0 (Reference) 
Preeclampsia 32 (24.4) 154 (11.0) 1505 (5.1) 
Crude RR (95% CI) 4.8 (3.5-6.5) 2.1 (1.8-2.5) 1.0 (Reference) 
Adjusted RR (95% CI)a 3.6 (2.6-5.0) 1.9 (1.6-2.3) 1.0 (Reference) 
Placental abruption 6 (4.6) 41 (2.9) 392 (1.3) 
Crude RR (95% CI) 3.4 (1.6-7.5) 2.2 (1.6-3.0) 1.0 (Reference) 
Adjusted RR (95% CI)a 2.7 (1.2-6.1) 2.0 (1.4-2.8) 1.0 (Reference) 
Small for gestational age 31 (23.7) 290 (20.7) 3499 (11.9) 
Crude RR (95% CI) 2.0 (1.5-2.7) 1.7 (1.6-1.9) 1.0 (Reference) 
Adjusted RR (95% CI)a 1.9 (1.4-2.7) 1.7 (1.5-1.9) 1.0 (Reference) 
Small for gestational age <3rd percentile 
Ischemic placental disease or 
IUFD 44 (33.6) 260 (18.6) 2594 (8.8) 
Crude RR (95% CI) 3.8 (3.0-4.9) 2.1 (1.9-2.4) 1.0 (Reference) 
Adjusted RR (95% CI)a 3.0 (2.3-3.9) 1.9 (1.7-2.2) 1.0 (Reference) 
Small for gestational age 10 (7.6) 85 (6.1) 824 (2.8) 
Crude RR (95% CI) 2.7 (1.5-5.0) 2.2 (1.7-2.7) 1.0 (Reference) 
Adjusted RR (95% CI)a 2.3 (1.3-4.4) 2.0 (1.6-2.5) 1.0 (Reference) 
IVF: In vitro fertilization; IUFD: Intrauterine fetal demise 
Data presented as n (%) or risk ratio (RR) and 95% confidence interval (CI) 
a Adjusted for maternal age 
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Table 2.11: Hazard ratios for ischemic placental disease and ischemic placental 
disease components in donor and autologous in vitro fertilization (IVF) groups 
compared with non-IVF group 
 Donor IVF 
(n=206) 
Autologous IVF 
(n=2132) 
Non-IVF 
(n=64114) 
Small for gestational age <10th percentile 
Ischemic placental disease 
or IUFD 74 (35.9) 568 (26.6) 8647 (13.5) 
Crude HR (95% CI) 3.8 (3.0-4.7) 2.7 (2.5-3.0) 1.0 (Reference) 
Adjusted HR (95% CI)a 3.6 (2.9-4.6) 2.6 (2.4-2.8) 1.0 (Reference) 
Preeclampsia 39 (18.9) 180 (8.4) 2358 (3.7) 
Crude HR (95% CI) 6.6 (4.8-9.1) 2.9 (2.5-3.7) 1.0 (Reference) 
Adjusted HR (95% CI)a 4.6 (3.3-6.5) 2.3 (2.0-2.7) 1.0 (Reference) 
Placental abruption 9 (4.4) 69 (3.2) 839 (1.3) 
Crude HR (95% CI) 4.1 (2.1-7.9) 3.0 (2.3-3.8) 1.0 (Reference) 
Adjusted HR (95% CI)b 3.7 (1.9-7.2) 2.9 (2.2-3.7) 1.0 (Reference) 
Small for gestational age 45 (21.8) 398 (18.7) 6091 (9.5) 
Crude HR (95% CI) 3.4 (2.5-4.6) 2.8 (2.5-3.1) 1.0 (Reference) 
Adjusted HR (95% CI)a 3.6 (2.7-4.9) 2.8 (2.5-3.1) 1.0 (Reference) 
Small for gestational age <3rd percentile 
Ischemic placental disease 
or IUFD 55 (26.7) 342 (16.0) 4435 (6.9) 
Crude HR (95% CI) 5.1 (3.9-6.7) 3.0 (2.7-3.4) 1.0 (Reference) 
Adjusted HR (95% CI)a 4.2 (3.2-5.5) 2.7 (2.4-3.0) 1.0 (Reference) 
Small for gestational age 12 (5.8) 118 (5.5) 1418 (2.2) 
Crude HR (95% CI) 3.9 (2.2-6.8) 3.6 (2.9-4.3) 1.0 (Reference) 
Adjusted HR (95% CI)a 4.9 (2.2-7.0) 3.5 (2.8-4.2) 1.0 (Reference) 
IVF: In vitro fertilization; IUFD: Intrauterine fetal demise 
Data presented as n (%) or hazard ratio (HR) and 95% confidence interval (CI) 
a Adjusted for age and parity 
b Adjusted for age 	  
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Table 2.12: Comparison of donor in vitro fertilization (IVF) group and propensity 
score matched non-IVF group on baseline characteristics (n=380) 
 Donor IVF 
(n=190) 
Non-IVF 
(n=190) 
Demographic characteristics   
Maternal age (years) 41.8 (38.3-44.1) 38.8 (31.2-44.1) 
Race   
Caucasian 156 (82.1) 130 (68.4) 
African American 10 (5.3) 16 (8.4) 
Hispanic 1 (0.5) 7 (3.7) 
Asian 5 (2.6) 11 (5.8) 
Other 8 (4.2) 5 (2.6) 
Not reported/unknown 10 (5.3) 21 (11.1) 
Marital status   
Married or partnered 167 (87.9) 151 (79.5) 
Single 19 (10.0) 33 (17.4) 
Divorced, separated or widowed 2 (1.1) 2 (1.1) 
Unknown 2 (1.1) 4 (2.1) 
Gravidity   
1 116 (61.1) 102 (53.7) 
2 41 (21.6) 38 (20.0) 
3+ 33 (17.4) 50 (26.3) 
Parity   
0 120 (63.2) 115 (60.5) 
1 53 (27.9) 50 (26.3) 
2 14 (7.4) 16 (8.4) 
3+ 3 (1.6) 9 (4.7) 
Insurance   
Public  2 (1.1) 8 (4.2) 
Private, other 188 (98.9) 181 (95.3) 
Uninsured 0 (0.0) 1 (0.5) 
IVF: In vitro fertilization 
Data presented as median (interquartile range) or n (%) 
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Table 2.13: Risk ratios for ischemic placental disease and ischemic placental disease 
components in autologous in vitro fertilization (IVF) groups compared with 
propensity score matched non-IVF group  
 
 Donor IVF 
(n=190) 
Non-IVF 
(n=190) 
Small for gestational age <10th percentile 
Ischemic placental disease or IUFD 68 (35.8) 39 (20.5) 
Crude RR (95% CI) 1.7 (1.2-2.5) 1.0 (Reference) 
Preeclampsia 36 (20.5) 8 (4.2) 
Risk ratio (95% CI) 4.5 (2.1-9.4) 1.0 (Reference) 
Placental abruption 9 (4.7) 2 (1.1) 
Risk ratio (95% CI) 4.5 (0.98-20.6) 1.0 (Reference) 
Small for gestational age 41 (21.6) 33 (17.4) 
Risk ratio (95% CI) 1.2 (0.8-1.9) 1.0 (Reference) 
Small for gestational age <3rd percentile 
Ischemic placental disease or IUFD 51 (26.8) 19 (10.0) 
Risk ratio (95% CI) 2.7 (1.6-4.4) 1.0 (Reference) 
Small for gestational age 11 (5.8) 9 (4.7) 
Risk ratio (95% CI) 1.2 (0.5-2.9) 1.0 (Reference) 
IVF: In vitro fertilization; IUFD: Intrauterine fetal demise 
Data presented as n (%) or risk ratio and 95% confidence interval (CI) 
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Table 2.14: Comparison of autologous in vitro fertilization (IVF) group and 
propensity score matched non-IVF group on baseline characteristics (n=4,214) 
 Autologous IVF 
(n=2,107) 
Non-IVF 
(n=2,107) 
Demographic characteristics   
Maternal age at conception (years) 35.8 (32.8-38.8) 35.4 (31.4-39.1) 
Race   
Caucasian 1,644 (78.0) 1,499 (71.1) 
African American 76 (3.6) 127 (6.0) 
Hispanic 36 (1.7) 75 (3.6) 
Asian 132 (6.3) 200 (9.5) 
Other 81 (3.8) 85 (4.0) 
Not reported/unknown 138 (6.5) 121 (5.7) 
Marital status   
Married or partnered 1,956 (82.8) 1,833 (87.0) 
Single 100 (4.7) 210 (10.0) 
Divorced, separated, widowed 17 (0.8) 24 (1.1) 
Unknown/missing 34 (1.6) 40 (1.9) 
Gravidity   
1 1,419 (67.3) 1,212 (57.5) 
2 349 (16.6) 461 (21.9) 
3+ 339 (16.1) 434 (20.6) 
Parity   
0 1,319 (66.0) 1,318 (62.6) 
1 612 (29.0) 589 (28.0) 
2 84 (4.0) 143 (6.8) 
3+ 20 (0.9) 57 (2.7) 
Insurance   
Public  20 (0.9) 155 (7.4) 
Private, self-pay, other 2,086 (99.0) 1,948 (92.5) 
Uninsured 1 (0.05) 4 (0.2) 
IVF: In vitro fertilization 
Data presented as median (interquartile range) or n (%) 
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Table 2.15: Risk ratios for ischemic placental disease and ischemic placental disease 
components in autologous in vitro fertilization (IVF) groups compared with 
propensity score matched non-IVF group  
 
 Autologous IVF 
(n=2080) 
Non-IVF 
(n=2080) 
Small for gestational age <10th percentile 
Ischemic placental disease or IUFD 562 (26.7) 329 (15.6) 
Risk ratio (95% CI) 1.7 (1.5-1.9) 1.0 (Reference) 
Preeclampsia 178 (8.4) 101 (4.8) 
Risk ratio (95% CI) 1.8 (1.4-2.2) 1.0 (Reference) 
Placental abruption 68 (3.2) 34 (1.6) 
Risk ratio (95% CI) 2.0 (1.3-3.0) 1.0 (Reference) 
Small for gestational age 393 (18.7) 230 (10.9) 
Risk ratio (95% CI) 1.7 (1.5-2.0) 1.0 (Reference) 
Small for gestational age <3rd percentile 
Ischemic placental disease or IUFD 340 (16.1) 175 (8.3) 
Risk ratio (95% CI) 1.9 (1.6-2.3) 1.0 (Reference) 
Small for gestational age 118 (5.6) 47 (2.2) 
Risk ratio (95% CI) 2.5 (1.8-3.5) 1.0 (Reference) 
IVF: In vitro fertilization; IUFD: Intrauterine fetal demise 
Data presented as n (%) or risk ratio and 95% confidence interval (CI) 
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Table 2.16: Probabilistic quantitative bias analysis correcting for non-differential 
exposure and outcome misclassification 
 Donor IVF compared with 
non-IVF 
Autologous IVF compared 
with non-IVF 
Observed (crude) RR (95% 
confidence interval) 
2.6 (2.2-3.1) 1.9 (1.7-2.0) 
Exposure misclassification 
Corrected for systematic 
error, RR (simulation 
interval) 
2.60 (2.60-2.61) 1.97 (1.94 - 2.02) 
Total corrected, RR 
(simulation interval) 
2.60 (2.16-3.14) 1.97 (1.82 - 2.13) 
Outcome misclassification 
Corrected for systematic 
error, RR (simulation 
interval) 
7.80 (3.9 - 139.24) 4.94 (2.68 - 83.58) 
Total corrected, RR 
(simulation interval) 
7.88 (3.81 - 139.55) 4.95 (2.67 - 84.38) 
IVF: In vitro fertilization; RR: Risk ratio 
Simulation interval: 2.5th-97.5th percentile 
Total corrected for systematic and random error 
Exposure misclassification sensitivity: minimum 35%; mode 1 50%; mode 2 70%; 
maximum 80% 
Exposure misclassification specificity: 100% 
Outcome misclassification sensitivity: minimum 60%; mode 1 70%; mode 2 75%; 
maximum 80% 
Outcome misclassification specificity: minimum 80%; mode 90%; maximum 95%	  
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2.7 FIGURES 
Figure 2.1: Comparison of distribution of propensity scores in the donor in vitro 
fertilization (IVF) group and non-IVF group 
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Figure 2.2: Comparison of distribution of propensity scores in the autologous in 
vitro fertilization (IVF)and non-IVF groups 		
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3.0 ELEVATED SERUM PROGESTERONE DURING IN VITRO 
FERTILIZATION TREATMENT AND THE RISK OF ISCHEMIC PLACENTAL 
DISEASE  
 
3.1 BACKGROUND  
 Progesterone is a hormone that prepares the uterine lining for implantation and 
subsequent placentation.1 During an in vitro fertilization (IVF) cycle, proper timing of 
increases and decreases in progesterone levels is important, so that the uterus is prepared 
when the embryo is transferred, but not before.1,2 As such, prior to oocyte retrieval and 
embryo transfer, women are given medications to suppress serum progesterone. 
Consequently, serum progesterone is measured before and on the day when human 
chorionic gonadotropin (hCG) is administered to induce the final stages of oocyte 
maturation in preparation for oocyte retrieval.1 Despite progesterone suppression, 
progesterone levels will be elevated in some women,3–5 and prematurely elevated serum 
progesterone in the IVF cycle has been shown to be associated with abnormal 
placentation3,5 and a decreased probability of clinical pregnancy and live birth,6–8 
although the evidence has been mixed.4,5,7,8  
One potential consequence of abnormal placentation, specifically insufficient 
placentation, is ischemic placental disease (IPD),9–11 which is defined as preeclampsia, 
placental abruption, and/or small for gestational age (SGA).12 These three conditions can 
occur separately; however, they often co-occur and are thought to have shared risk 
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factors.12,13 IPD is a serious adverse outcome, affecting both the mother and infant,11,13 
and understanding the mechanism and risk factors is important. 
Given that serum progesterone is important for implantation and placentation, 
abnormalities in the timing of elevated progesterone may lead to placental disorders. 
While there is some evidence that prematurely elevated progesterone may decrease live 
birth rates, little is known about whether elevated progesterone is associated with adverse 
outcomes among live births. We conducted a cohort study to evaluate the hypothesis that 
women with elevated endogenous serum progesterone on the day of hCG administration 
have a higher risk of IPD compared with women who do not have elevated serum 
progesterone. 
 
 
3.2 METHODS 
3.2.1 Study population 
Our study population comprised all autologous (using the woman’s own oocytes) 
IVF deliveries at Beth Israel Deaconess Medical Center (BIDMC), a large tertiary care 
hospital, with an available endogenous progesterone level on the day of hCG 
administration. They were identified from an existing cohort of IVF cycles performed at 
Boston IVF, the infertility treatment center affiliated with BIDMC, that have been linked 
to deliveries at BIDMC. We limited our population to individuals who had a delivery at 
or after 20 weeks of gestation.  
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3.2.2 Description of parent cohort 
Although Boston IVF and BIDMC are affiliated, they maintain separate electronic 
medical records and do not have a unique identifier to link IVF cycles and deliveries. 
Therefore, a multi-step approach was used to link IVF cycles and deliveries. Maternal 
last name, date of birth, and start of the menstrual cycles were used as the matching 
variables. First, all IVF cycles performed at Boston IVF from January 1, 1999 to June 1, 
2015 were identified electronically using clinic-specific procedure codes. We calculated 
the start of the menstrual cycle from both data sources. From the BIDMC delivery 
information, the first day of the last menstrual period (LMP) was calculated by 
subtracting the gestational age at delivery from the date of delivery and the cycle start 
date was used from the Boston IVF data. To allow for possible errors in gestational age 
dating, we created a window of 28 days before and 28 days after the LMP. An eight-week 
window was chosen in order to ensure that we were adequately capturing the start of the 
pregnancy due to differences in the length of an IVF cycle for each woman, while not 
allowing a large enough window to capture a second pregnancy after a potentially failed 
IVF cycle. Two approaches were used to match the data. First, matches were identified if 
the cycle start date from the IVF records fell within the 56-day window and the maternal 
date of birth and last name was identical. Due to concerns about spelling differences of 
the last name between the two datasets, a second match was done on the remaining cycles 
and deliveries using only the 56-day window and maternal date of birth. We reviewed the 
matches identified using these relaxed criteria to confirm the match. 
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3.2.3 Progesterone 
Progesterone levels were recorded on day of hCG administration if the patient had 
blood work analyzed at Boston IVF. Recording of progesterone in the Boston IVF 
electronic records began in June 2005 and only pregnancies with available progesterone 
were included in the analysis. In September 2012, Boston IVF changed the progesterone 
analyzer from the IMMULITE 2000 Analyzer, Siemens (Munich, Germany) to the 
COBAS e411, Roche (Basel, Switzerland), resulting in overall progesterone levels being 
slightly higher after this change.  
 
3.2.4 Ischemic placental disease 
The primary outcome was IPD (the presence of preeclampsia, placental abruption, 
SGA), or an intrauterine fetal demise (IUFD) where the cause was related to placental 
insufficiency. SGA is defined as a birthweight below the 10th percentile within strata of 
gestational age at delivery and infant sex. A US sample was used as the standard growth 
curve.14 In the case of multiple gestations, if any of the infants met criteria for SGA, the 
pregnancy was classified as being affected by SGA. Infant birthweight and sex were 
abstracted from the hospital administrative database for live births and abstracted 
individually from the medical record for IUFDs. Birthweight was missing for two infants.  
We identified potential cases of preeclampsia using ICD9 diagnosis codes 642.40-
642.44, 642.50-642.54, 642.60-642.64, 642.70-642.74, 642.51, and 642.53 from 
administrative hospital databases. Due to concerns about misclassification of 
preeclampsia, electronic medical records were reviewed for the presence of elevated 
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blood pressure (>140/80) during the delivery admission and either symptoms of 
preeclampsia (headache, visual changes, severe abdominal pain, or seizures) or abnormal 
laboratory values (proteinuria, alanine aminotransferase (ALT)/aspartate 
aminotransferase (AST) >80 units per liter, or platelets <100,000) occurring before 
delivery.  
We identified potential cases of placental abruption using ICD9 diagnosis codes 
641.20-641.23 from administrative hospital databases. To confirm cases of placental 
abruption, we reviewed the medical record for evidence of abruption or blood clot during 
a delivery; evidence of abruption on placental pathology; or a very strong clinical 
suspicion of abruption that required hospitalization, intervention, and delivery.  
Pregnancies resulting in an IUFD were identified using ICD9 diagnosis codes 
(656.41, 656.43, V27.1) from administrative hospital databases and were confirmed by 
medical record review. We reviewed autopsy, pathology, and clinical notes for evidence 
of placental insufficiency as a cause of the IUFD.  
Medical records were reviewed by research staff and any questions related to the 
review were additionally reviewed by a fellowship-trained maternal-fetal medicine 
physician. Reviewers were blinded to progesterone levels on the day of hCG 
administration.  
Due to institutional changes in medical records, medical record data sufficient to 
confirm preeclampsia and placental abruption were only available after July 1, 2008. 
Therefore, we were able to review medical records for 60.8% of preeclampsia diagnoses 
and 40.8% of placental abruption diagnoses identified by ICD9 codes. Among the 
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reviewed records, 88.5% of the preeclampsia ICD9 codes were confirmed and 93.1% of 
the abruption ICD9 codes were confirmed. Cases that could not be confirmed were 
considered to not have the diagnosis. Diagnoses of preeclampsia and placental abruption 
for which medical records were unavailable were defined only by the ICD9 codes.  
 
3.2.5 Covariates 
Demographic data and delivery outcomes were gathered electronically. Maternal 
age, race/ethnicity, marital status, and insurance were self-reported by the mother during 
hospital registration. One primary infertility diagnosis was recorded by the reproductive 
endocrinologist at Boston IVF at the start of the IVF cycle. Gravidity, parity, gestational 
age at delivery, mode of delivery, infant sex, birth weight, and Apgar scores were 
recorded by a clinician after delivery. All women were gravid because gravidity and 
parity refer to the pregnancy being studied. However, if this was the woman’s first 
pregnancy (gravidity=1), she was considered nulliparous (parity=0). Pregnancies with 
multiple gestations could have more than one mode of delivery and infant sex. In 
addition, each infant had their own birth weight and Apgar scores.  
For IUFDs, only registration and infertility diagnosis data were available 
electronically. Therefore, the remaining covariate data were abstracted from the medical 
record, when available.  
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3.2.6 Statistical analysis 
Progesterone was divided into tertiles based on the distribution of progesterone in 
the cohort. In order to address the change in progesterone analyzer, the tertiles were 
created within each analyzer time period, and then combined to create tertiles for the 
cohort. The lowest tertile (tertile 1) was used as the reference category. Risk ratios (RR) 
and 95% confidence intervals (CI) were calculated using generalized estimating equation 
models with a binomial distribution, adjusted for within-person correlation using an 
independent correlation matrix, given women could have multiple pregnancies during the 
study period. Potential confounders were chosen based on the literature, as well as an 
assessment of covariates that differed by exposure and outcome. All models were 
adjusted for maternal age at the last menstrual period as a continuous variable. We 
adjusted for gravidity (1 or 2+), parity (0 or 1+), race/ethnicity (Caucasian or not 
Caucasian), year of delivery, and the progesterone machine used; each covariate was 
individually included in the regression model with progesterone and age. The covariate 
that had the strongest effect on the RR was maintained in the model, and this process was 
repeated until no covariate changed the RR by more than 10%. 
We conducted several sensitivity analyses. Due to concerns about missing 
progesterone levels in 85% of the original cohort, we evaluated differences in covariate 
and outcome data between women with and without data on progesterone. Since there is 
no standard cut off value for progesterone,8 we explored progesterone as both a 
continuous and categorical variable. First, we compared the median progesterone levels 
among women with and without each outcome. In a prior review, 0.9 ng/ml was reported 
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as a common cut off for progesterone levels,4 and we compared outcomes in women with 
progesterone ≥0.9 ng/ml to women with progesterone <0.9 ng/ml on the day of hCG 
administration. We used restricted cubic spline regression models to assess progesterone 
as a continuous variable.15 The 25th, 50th, and 75th percentile for progesterone were 
chosen as the knots. Progesterone levels were truncated at the 99th percentile to decrease 
the effect of extreme levels. The restricted cubic splines were adjusted for maternal age at 
the LMP.  
 
3.3 RESULTS 
3.3.1 Baseline demographics 
We identified 329 IVF deliveries with available progesterone on the day of hCG 
administration, with 108 deliveries in the lowest tertile (range 0.2-0.73 ng/ml) and 112 
deliveries in the middle tertile (range 0.56-1.05 ng/ml) and 109 deliveries in the highest 
tertile (range 0.96-4.4 ng/ml). Overall, the median progesterone was 0.80 ng/ml. 
Progesterone tertiles were similar with respect to maternal age, marital status, and 
insurance status. Asian women were more likely to have higher progesterone than 
African American women and women of “Other” races. Women with ovarian 
dysfunction and diminished ovarian reserve had lower progesterone. (Table 3.1.)  
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3.3.2 Pregnancy outcomes 
The incidence of preterm delivery was 33.9% in the highest tertile compared with 
22.3% in the lowest tertile. We did not observe differences in any other immediate 
delivery outcomes across progesterone tertiles. The median gestational age at delivery 
was approximately 38 weeks in each tertile, and there were two IUFDs. One quarter of 
the pregnancies had multiple gestations, and this also did not differ by progesterone 
levels (Table 3.2). 
 
3.3.3 Incidence of ischemic placental disease 
Overall, 26.7% of the cohort had IPD. There were only two IUFDs in the cohort 
and neither was attributed to placental insufficiency. After adjusting for maternal age, 
both the middle (RR: 2.0, 95% CI: 1.3-3.3) and highest tertiles (RR: 1.6, 95% CI: 0.6-
2.6) of progesterone had a higher risk of IPD compared with the lowest tertile. Adjusting 
for other covariates did not appreciably alter the RRs. Of note, for the placental abruption 
models, we did not control for additional covariates beyond age due to small numbers. 
The risk of preeclampsia also was higher in the middle (RR: 3.6, 95% CI: 1.3-9.2) and 
highest (RR: 2.0, 95% CI: 0.7-5.7) tertiles of progesterone relative to the lowest tertile. 
The RRs for placental abruption also tended to be higher in the middle and highest 
tertiles of progesterone relative to the lowest tertile; however, the RRs were imprecise 
due to the small number of placental abruptions. We saw an increased risk of SGA in the 
middle tertile (RR: 1.9, 95% CI: 0.96-2.9) but we did not see a difference in SGA in the 
highest tertile, compared to the lowest tertile of progesterone (Table 3.3). 
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3.3.4 Sensitivity analyses 
IVF deliveries with available progesterone levels (15%) were similar to those 
without progesterone (85%) with respect to maternal age, race, marital status, gravidity, 
parity, and insurance, and the pregnancy outcomes assessed herein (Table 3.4). 
When progesterone was coded as a continuous variable, we did not find any 
difference in median progesterone comparing women with and without IPD, 
preeclampsia, placental abruption, and SGA (Table 3.5).  
Women with elevated progesterone based on a cutoff of ≥0.9 ng/ml had 1.3 (95% 
CI: 0.9-1.9) times the risk of IPD compared with women with lower progesterone when 
adjusted for maternal age. We saw similarly elevated risks for preeclampsia and SGA 
when we adjusted for maternal age (RR: 1.2, 95% CI: 0.7-2.3 and RR: 1.3, 95% CI 0.8-
2.0, respectively). Similar to the primary analysis, there were too few placental abruption 
cases to draw meaningful conclusions (Table 3.6). 
The restricted cubic spline analyses were generally consistent with the categorical 
analyses. The regression analysis for preeclampsia could not be adjusted for maternal age 
due to the small sample size. The RRs for each outcome tended to increase with 
increasing progesterone up until the middle of the progesterone distribution (0.8-1.0 
ng/ml) and then decrease slightly. (Figures 3.1-3.4) 
 
3.4 DISCUSSION 
In this study, we found an elevated risk of IPD in women with higher serum 
progesterone on the day of hCG administration compared with women with lower levels, 
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although we had a small sample size and our results were imprecise. We saw an increased 
risk of preeclampsia in women in the middle and highest tertiles of progesterone, but we 
did not see an increase in SGA in the highest tertile SGA. We did not have sufficient 
cases of placental abruption to draw a meaningful conclusion. Using a 0.9 ng/ml cut off 
for “high” progesterone levels also indicated an increased risk for IPD, as well as 
preeclampsia and SGA, in women with elevated progesterone.  
Prior literature has shown a decrease in the incidence of live birth among women 
with elevated progesterone, and it is believed that elevated progesterone on the day of 
hCG administration may deleteriously affect placentation, leading to a decrease in 
clinical pregnancies and live births.4,6–8,16 However, when restricted to cycles that results 
in pregnancies ≥20 weeks of gestation, progesterone on the day of hCG administration 
does not appear to have a strong effect on IPD based on the results of this study. One 
explanation for this phenomenon is that progesterone may not have a sufficient influence 
on placentation to increase IPD risk among those who achieve a pregnancy lasting at least 
20 weeks of gestation. In addition, progesterone may affect the probability of a live birth 
through a mechanism not related to IPD. Finally, progesterone on the day of hCG 
administration may need to be higher than what was observed in our study population in 
order to see an association. Some studies have proposed cut off values of 1.5 ng/ml for 
progesterone;6 however, we did not see many women with levels that high in our cohort. 
It is possible that providers are less likely to continue with an IVF cycle at higher 
progesterone levels due to concerns about decreased clinical pregnancies and live births.  
An important limitation was small sample size. In addition, tertiles of exposure 
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were determined based on the distribution of progesterone in our data, and these 
categories may not be clinically relevant or applicable to other datasets. However, we 
conducted several sensitivity analyses using progesterone as a dichotomous and a 
continuous exposure with similar results. We also were missing progesterone on 85% of 
women from the original cohort, which could have introduced selection bias. There were 
few differences in demographic characteristics and IPD between those with and without 
progesterone; therefore, we do not believe that selection bias from this mechanism is 
present here. 
Our use of ICD9 codes may have allowed for outcome misclassification. We were 
able to confirm some of the ICD9 codes but were limited by the availability of medical 
records prior to July 1, 2008. The ICD9 codes had high positive predictive value; 
however, there likely are women classified as having preeclampsia or placental abruption 
who were not true cases during the study time period that medical records were not 
available. Conversely, it is possible that women had preeclampsia or placental abruption 
who did not receive the proper ICD9 code and thus were not captured; although, this 
scenario likely is rare given the severity of preeclampsia and placental abruption and the 
need for obstetric intervention in both cases. At our institution, the obstetrical team does 
not have access to the IVF laboratory results, and thus were blinded to progesterone 
levels on the day of hCG administration. Therefore, we do not believe that outcome 
misclassification would be related to exposure, and we believe the overall effect of any 
non-differential outcome misclassification would be small in this study. 
Our use of singleton growth curves to assess SGA in multiples may have led to an 
		
59 
over-diagnosis of SGA. The proportion of multiples was similar across the three tertiles; 
however, given our use of tertiles, it is difficult to determine the direction of the bias. It is 
also possible that we are missing IUFDs that were caused by placental insufficiency due 
to the difficulty in determine causes for IUFDs. There were only two IUFDs in this 
cohort, and neither of them was determined to be related to placental insufficiency. Given 
the small number, it is not likely that this would have had a large effect on our estimates. 
We were not able to control for potentially important confounders such as body 
mass index, maternal diabetes, smoking, and other medical history because they were not 
available in the electronic medical records. While these are risk factors for infertility and 
IPD, it is not known whether they are related to progesterone levels on the day of hCG 
administration. If they are not related to progesterone, we would not be concerned about 
residual confounding. 
Another limitation is our use of data from one institution. Although the IVF 
groups in our study were not very diverse with regards to race/ethnicity and 
socioeconomic status, they are from one of the largest IVF providers and are 
representative of IVF populations in other studies. Our use of deliveries from a single 
institution may limit our generalizability given it is a tertiary care center. It also is 
important to note that we limited to pregnancies ≥20 weeks of gestation, and our results 
would not be applicable to pregnancies that end prior to 20 weeks of gestation. 
In this study, we were able to assess the association between progesterone and 
risk of IPD, not just pregnancy or live birth, as has been done in other studies.3–8 In 
addition, exposure, outcome, and covariate data were recorded prospectively in the 
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medical records. The use of a composite outcome, IPD, comprised of four individual 
pregnancy complications that share a common set of risk factors, also is a strength. 
Preeclampsia, placental abruption, and SGA can co-occur in pregnancies13 and using IPD 
as our outcome allowed us to examine the relationship between IVF and a group of 
biologically-related complications and is helpful in clarifying a causal mechanism. 
 
 
3.5 CONCLUSION 
In a population of women undergoing IVF, elevated serum progesterone on the 
day of hCG administration was associated with an increased risk of IPD, preeclampsia, 
and SGA. However, small numbers precluded us from assessing the effect of 
progesterone on placental abruption. Larger studies are needed to explore this 
relationship further. 	  
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3.6 TABLES 
Table 3.1 Baseline characteristics of patients who delivered and had available 
progesterone levels on the day of hCG administration by tertile of progesterone 
 Whole cohort 
(n=329) 
Tertile 1 – 
(0.2-0.73 
ng/ml) 
(n=108) 
Tertile 2 – 
(0.56-1.05 
ng/ml) 
(n=112) 
Tertile 3 –  
(0.96-4.4 
ng/ml) 
(n=109) 
Progesterone (ng/ml) 0.80 
(0.56-1.13) 
0.48  
(0.37-0.56) 
0.80  
(0.72-0.90) 
1.30 
(1.13-1.51) 
Demographic characteristics     
Maternal age at last menstrual 
period (years) 
35.6  
(32.9-38.5) 
35.5  
(32.6-38.3) 
35.6  
(32.8-38.8) 
35.7 
(33.2-38.3) 
Race     
Caucasian 238 (72.3) 78 (72.2) 81 (72.3) 79 (72.5) 
African American 14 (4.3) 6 (5.6) 4 (3.6) 4 (3.7) 
Hispanic 5 (1.5) 1 (0.9) 0 (0.0) 4 (3.7) 
Asian 31 (9.4) 8 (7.4) 10 (8.9) 13 (11.9) 
Other 20 (6.1) 7 (6.5) 10 (8.9) 3 (2.8) 
Not reported/unknown 21 (6.3) 8 (7.4) 7 (6.3) 6 (5.5) 
Marital status     
Married 302 (91.8) 99 (91.7) 103 (92.0) 100 (91.7) 
Partnered, but not married 1 (0.3) 0 (0.0) 1 (0.9) 0 (0.0) 
Single 20 (6.1) 6 (5.6) 7 (6.3) 7 (6.4) 
Divorced 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.9) 
Widowed 1 (0.3) 1 (0.9) 0 (0.0) 0 (0.0) 
Unknown/missing 4 (1.2) 2 (1.9) 1 (0.9) 1 (0.9) 
Gravidity     
1 221 (67.2) 76 (70.4) 74 (66.1) 71 (65.1) 
2 50 (15.2) 14 (13.0) 22 (19.6) 14 (12.8) 
3+ 58 (17.6) 18 (16.7) 16 (14.3) 24 (22.0) 
Parity     
0 222 (67.5) 76 (70.4) 71 (63.4) 75 (68.8) 
1 88 (26.7) 28 (25.9) 31 (27.7) 29 (26.6) 
2 17 (5.2) 4 (3.7) 9 (8.0) 4 (3.7) 
3+ 2 (0.6) 0 (0.0) 1 (0.9) 1 (0.9) 
Insurance     
Public  1 (0.3) 1 (0.9) 0 (0.0) 0 (0.0) 
Private, other 328 (99.7) 107 (99.1) 112 (100.0) 109 (100.0) 
Primary infertility diagnosis     
Female infertility     
Diminished ovarian reserve 25 (7.6) 10 (9.3) 11 (9.8) 4 (3.7) 
Ovarian dysfunction 18 (5.5) 8 (7.4) 6 (5.4) 4 (3.7) 
Endometriosis 8 (2.4) 4 (3.7) 1 (0.9) 3 (2.8) 
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Tubal factor 6 (1.8) 2 (1.9) 1 (0.9) 3 (2.8) 
Uterine factor 3 (0.9) 1 (0.9) 0 (0.0) 2 (1.8) 
Other 34 (10.3) 9 (8.3) 13 (11.6) 12 (11.0) 
Male factor infertility 75 (22.8) 25 (23.1) 19 (17.0) 31 (28.4) 
Unexplained 142 (43.2) 45 (41.7) 52 (46.4) 45 (41.3) 
Missing 18 (5.5) 4 (3.7) 9 (8.0) 5 (4.6) 
Change in progesterone analyzer     
Before change 179 (54.4) 59 (54.6) 60 (53.6) 60 (55.0) 
After change 150 (45.6) 49 (45.4) 52 (46.4) 49 (45.0) 
Data are presented as median (interquartile range) or n (%) 	  
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Table 3.2: Immediate pregnancy and delivery outcomes of cohort by tertile of 
progesterone level in a cohort of 329 deliveries from 2005 to 2015 
 Whole cohort 
(n=329) 
Tertile 1 
(n=108) 
Tertile 2 
(n=112) 
Tertile 3 
(n=109) 
Gestational age at delivery 
(weeks) 
38.0 
(36.0-39.3) 
38.8 
(37.0-39.6) 
38.0 
(36.0-39.3) 
38.3 
(36.0-39.0) 
Preterm delivery (<37 
weeks of gestation) 101 (30.7) 24 (22.3) 40 (35.7) 37 (33.9) 
Intrauterine fetal demise 2 (0.6) 0 (0.0) 1 (0.9) 1 (0.9) 
Mode of delivery     
Vaginal 136 (41.3) 52 (48.1) 38 (33.9) 46 (42.2) 
Cesarean 177 (53.8) 52 (48.1) 67 (59.8) 58 (53.2) 
Vaginal and cesarean 
delivery† 
14 (4.3) 4 (3.7) 6 (5.4) 4 (3.7) 
Missing 2 (0.6) 0 (0.0) 1 (0.9) 1 (0.9) 
Gestations     
Singleton 246 (74.8) 86 (79.6) 78 (69.6) 82 (75.2) 
Multiple 83 (25.2) 22 (20.4) 34 (30.4) 27 (24.8) 
Singletons n=246 n=86 n=78 n=82 
Sex     
Female 112 (45.5) 43 (50.0) 32 (41.0) 37 (45.1) 
Male 134 (54.5) 43 (50.0) 46 (59.0) 45 (54.9) 
Birthweight (grams) 3225  
(2850-3580) 
3328  
(2970-3640) 
3138  
(2535-3520) 
3190  
(2855-3545) 
Apgar 1 minute€ 8.0 (8.0-9.0) 8.0 (8.0-9.0) 9.0 (8.0-9.0) 8.0 (8.0-9.0) 
Apgar 5 minutes€ 9.0 (9.0-9.0) 9.0 (9.0-9.0) 9.0 (9.0-9.0) 9.0 (9.0-9.0) 
Multiples* n=83 n=22 n=34 n=27 
Sex     
Female 25 (30.1) 7 (31.8) 8 (23.5) 10 (37.0) 
Male 20 (24.1) 4 (18.2) 7 (20.6) 9 (33.3) 
Both 38 (45.8) 11 (50.0) 19 (55.9) 8 (29.6) 
Birthweight  2195  
(1760-2830) 
2283 
(1760-2908) 
2283 
(1875-2748) 
2045 
(1558-2595) 
Apgar 1 minute€ 8.0 (7.0-8.5) 8.0 (7.5-8.0) 8.0 (7.5-8.5) 8.0 (6.5-8.0) 
Apgar 5 minutes€ 9.0 (8.0-9.0) 8.5 (8.0-9.0) 9.0 (8.5-9.0) 8.8 (8.0-9.0) 
Data presented as median (interquartile range) or n (%) 
† Some women who had multiples could delivery one infant vaginally and the second via 
cesarean 
€ For live births only 
* Birthweights and Apgar scores combined for all babies 
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Table 3.3: Risk ratios for ischemic placental disease and ischemic placental disease 
components in the second and third tertile of progesterone on the day of hCG 
administration, compared with the lowest tertile 
 Whole 
cohort 
(n=329) 
Tertile 1 
(n=108) 
Tertile 2 
(n=112) 
Tertile 3 
(n=109) 
Ischemic placental 
disease or IUFD 
    
N (%) with outcome 88 (26.7) 19 (17.6) 39 (34.8) 30 (27.5) 
Crude RR (95% CI)  1.0 (Reference) 2.0 (1.2-3.2) 1.6 (0.9-2.6) 
Adjusted RR (95% CI)*  1.0 (Reference) 2.0 (1.3-3.3) 1.6 (0.6-2.6) 
Preeclampsia     
N (%) with outcome 33 (10.0) 5 (4.6) 18 (16.1) 10 (9.2) 
Crude RR (95% CI)  1.0 (Reference) 3.5 (1.3-9.0) 2.0 (0.7-5.6) 
Adjusted RR (95% CI)*  1.0 (Reference) 3.6 (1.3-9.2) 2.0 (0.7-5.7) 
Placental abruption     
N (%) with outcome 7 (2.1) 1 (0.9) 3 (2.7) 3 (2.8) 
Crude RR (95% CI)  1.0 (Reference) 2.9 (0.3-27.5) 3.0 (0.3-28.1) 
Adjusted RR (95% CI)*  1.0 (Reference) 3.0 (0.3-29.0) 3.1 (0.3-30.6) 
Small for gestational age     
N (%) with outcome 63 (19.1) 16 (14.8) 27 (24.1) 20 (18.3) 
Crude RR (95% CI)  1.0 (Reference) 1.6 (0.9-2.8) 1.2 (0.7-2.3) 
Adjusted RR (95% CI)*  1.0 (Reference) 1.7 (0.96-2.9) 1.2 (0.7-2.3) 
IUFD: Intrauterine fetal demise 
Data are presented as risk ratio (RR) and 95% confidence interval (CI) or n (%) 
* Adjusted for maternal age at last menstrual period 	  
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Table 3.4: Comparison of demographic characteristics and ischemic placental 
disease in pregnancies with and without recorded progesterone level on the day of 
hCG administration 
 With progesterone 
(n=329) 
Without progesterone 
(n=1803) 
Demographic characteristics   
Maternal age at last menstrual 
period (years) 
35.6 (32.9-38.5) 35.9 (32.8-39.0) 
Race   
Caucasian 238 (72.3) 1429 (79.3) 
African American 14 (4.3) 63 (3.5) 
Hispanic 5 (1.5) 31 (1.7) 
Asian 31 (9.4) 101 (5.6) 
Other 20 (6.1) 62 (3.4) 
Not reported/unknown 21 (6.4) 117 (6.5) 
Marital status   
Married 302 (91.8) 1677 (93.0) 
Partnered, but not married 0 (0.0) 1 (0.1) 
Single 20 (6.1) 80 (4.4) 
Divorced 1 (0.3) 9 (0.5) 
Widowed 1 (0.3) 3 (0.2) 
Unknown/missing 4 (1.2) 30 (1.7) 
Gravidity   
1 221 (67.2) 1221 (67.7) 
2 50 (15.2) 299 (16.6) 
3+ 38 (17.6) 281 (15.6) 
Missing 0 (0.0) 2 (0.1) 
Parity   
0 222 (67.5) 1177 (65.3) 
1 88 (26.7) 531 (30.0) 
2 17 (5.2) 67 (3.7) 
3+ 2 (0.6) 18 (1.0) 
Insurance   
Public  1 (0.3) 19 (1.1) 
Private, other 328 (99.7) 1783 (98.9) 
Uninsured 0 (0.0) 1 (0.1) 
Primary infertility diagnosis   
Female infertility   
Diminished reserve 25 (7.6) 113 (6.3) 
Ovarian dysfunction 18 (5.5) 183 (10.1) 
Endometriosis 8 (2.4) 80 (4.4) 
Tubal 6 (1.8) 153 (8.5) 
Uterine 3 (0.9) 46 (2.6) 
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Other 34 (10.3) 117 (6.5) 
Male factor 75 (22.8) 379 (21.0) 
Unexplained 142 (43.2) 599 (33.2) 
Missing 18 (5.5) 133 (7.4) 
Outcomes   
Ischemic placental disease or IUFD 88 (26.7) 480 (26.6) 
Preeclampsia 33 (10.0) 147 (8.2) 
Placental abruption 7 (2.1) 62 (3.4) 
Small for gestational age 63 (19.1) 335 (18.6) 
IUFD: Intrauterine fetal demise 
Data are presented as median (interquartile range) or n (%) 
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Table 3.5: Median progesterone levels in those with ischemic placental disease 
compared with those without ischemic placental disease 
Diagnosis N Median (interquartile range) 
Ischemic placental disease or IUFD   
Yes 88 0.89 (0.62-1.2) 
No 241 0.77 (0.54-1.1) 
Preeclampsia   
Yes 33 0.88 (0.75-1.2) 
No 296 0.80 (0.54-1.1) 
Placental abruption   
Yes 7 0.90 (0.69-1.7) 
No 322 0.80 (0.56-1.1) 
Small for gestational age   
Yes 63 0.88 (0.59-1.2) 
No 266 0.80 (0.55-1.1) 
IUFD: Intrauterine fetal demise 	  
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Table 3.6: Progesterone levels and risk of ischemic placental disease and its 
components by progesterone level  
 Elevated progesterone, 
≥0.9 ng/ml 
(n=143) 
No elevated 
progesterone, <0.9 
ng/ml 
(n=186) 
Ischemic placental disease or IUFD 44 (30.8) 44 (23.7) 
Crude RR (95% CI) 1.3 (0.9-1.9) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.3 (0.9-1.9) 1.0 (Reference) 
Preeclampsia 16 (11.2) 17 (9.1) 
Crude RR (95% CI) 1.2 (0.6-2.3) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.2 (0.7-2.3) 1.0 (Reference) 
Placental abruption 4 (2.8) 4 (1.6) 
Crude RR (95% CI) 1.7 (0.4-7.6) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.8 (0.4-8.5) 1.0 (Reference) 
Small for gestational age 31 (21.7) 32 (17.2) 
Crude RR (95% CI) 1.3 (0.8-2.0) 1.0 (Reference) 
Adjusted RR (95% CI)* 1.3 (0.8-2.0) 1.0 (Reference) 
IUFD: Intrauterine fetal demise 
Data are presented as risk ratio (RR) and 95% confidence interval (CI) or n (%) 
* Adjusted for maternal age at last menstrual period  		  
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3.7 FIGURES 
Figure 3.1 Restricted cubic spline regression model of the risk of ischemic placental 
disease, adjusted for maternal age at last menstrual period, by level of progesterone 
on the day of hCG administration, knots at 0.56, 0.80, 1.13, reference 0.2 ng/ml 
 
 
	  
	 Risk	ratio	95%	confidence	interval	
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Figure 3.2 Restricted cubic spline regression model of the risk of preeclampsia by 
level of progesterone on the day of hCG administration, knots at 0.56, 0.80, 1.13, 
reference 0.2 ng/ml 	
 	  
	 Risk	ratio	95%	confidence	interval	
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Figure 3.3: Restricted cubic spline regression model of the risk of placental 
abruption, adjusted for maternal age at last menstrual period, by level of 
progesterone on the day of hCG administration, knots at 0.56, 0.80, 1.13, reference 
0.2ng/ml 
 
 	  
	 Risk	ratio	95%	confidence	interval	
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Figure 3.4 Restricted cubic spline regression model of the risk of small for 
gestational age, adjusted for maternal age at last menstrual period, by level of 
progesterone on the day of hCG administration, knots at 0.56, 0.80, 1.13, reference 
0.2 ng/ml 
 
 	  
	 Risk	ratio	95%	confidence	interval	
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4.0 USING INVERSE PROBABILITY-OF-CENSORING WEIGHTING TO 
ACCOUNT FOR TREATMENT DROP OUT WHEN CALCULATING 
CUMULATIVE INCIDENCE OF LIVE BIRTH IN AN IVF POPULATION 
 
4.1 BACKGROUND 
With increased use of in vitro fertilization (IVF) in the United States, it is 
important to quantify the overall rate of live birth. This information is helpful for patients, 
who want to understand and compare their treatment options; for clinicians, who need to 
counsel patients and evaluate their practices; and for other stakeholders, such as 
regulators and insurers, who need to ensure safety for IVF.1,2 The concept of an overall 
success rate is not always straightforward, particularly given many women undergo 
multiple IVF cycles to achieve a live birth.2 At the end of each cycle, if a woman does not 
have a pregnancy that results in live birth, she may go on to a subsequent IVF cycle. 
However, some women choose to stop treatment before they achieve a live birth. Prior 
research has shown that psychological burden related to IVF is one of the most common 
reason why women and couples discontinue treatment,3–5 particularly among those with 
insurance.4,6,7 Additional reasons include the increasing out-of-pocket costs, loss of 
insurance coverage, or a spontaneous pregnancy.6,8  
Different approaches have been used to measure IVF success, each with 
limitations. The Society for Assisted Reproductive Technology (SART) defines 
cumulative live birth as the probability of a live birth per oocyte retrieval (within one 
year of the retrieval).9 The live birth may have been from the initial fresh cycle or from 
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any subsequent frozen cycle that arose from the oocyte retrieval. There are several 
problems with this approach. The first is that it does not account for the fact that it may 
take more than one embryo retrieval for a woman to achieve live birth and therefore 
embryo retrieval cycles are not independent observations.2,8,10 Furthermore, a couple may 
undergo one fresh cycle and achieve a live birth, or one fresh cycle and two subsequent 
frozen cycles for a live birth; however, both would be considered one observation. 
Combing fresh and frozen cycles into one observation does not provide information about 
how many total cycles are needed to achieve a live birth. Considering the psychological 
burden of a failed IVF cycle,4 this information is important to patients. Another method 
used to quantify IVF success is the overall success per IVF cycle completed. Although 
this does take into account multiple cycles that arise from each oocyte retrieval, 
calculating live birth per IVF cycle is not a cumulative measure. In addition, live births 
per cycle does not take into account that some women may be on their first cycle, while 
others on their fourth or fifth cycle, and does not account for multiple cycles contributed 
by each woman.   
Other methods to estimate the cumulative incidence of live birth use traditional 
survival analysis and censor women who do not return for treatment despite not 
achieving a live birth. While this addresses some of the problems with the prior 
approaches, there are methodological challenges with survival analysis as well. Survival 
analysis methods assume that censoring is uninformative, meaning that the probability of 
success for those who are lost to follow up or drop out of treatment is the same as the 
average probability of success for those who stay in treatment; however, several studies 
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have found that women who do not return for treatment have a lower likelihood of 
achieving a live birth than women who remain in treatment.1,2,5,8 By censoring women 
who do not return for treatment, the results may suffer from a violation of the 
uninformative censoring assumption, thereby leading to selection bias due to loss to 
follow up or treatment dropout.2,11,12 If censored women have a lower probability of 
achieving live birth compared with women who remain in treatment, survival analysis 
will overestimate the cumulative incidence of live birth after IVF. In a prior study, 
Malizia et al.8 used two different approaches to acknowledge the issue of uninformative 
censoring. First, the authors estimated an “optimistic” scenario using standard survival 
analysis. Then, using the same cohort, they estimated a “conservative” scenario by 
forcing all women who were censored to stay in the model without a live birth. They 
found that using the “optimistic” approach, the cumulative incidence of live birth was 
72%, however, using the “conservative” approach, the cumulative incidence of live birth 
was only 51%. This difference can have a substantial impact on patient counseling and 
decision making.   
One potential method to adjust for loss to follow-up is inverse probability-of-
censoring weighted (IPCW) estimation.13 IPCW is similar to the inverse probability-of-
treatment weighting that is used to account for confounding.11,13 IPCW creates a pseudo-
population in which each uncensored cycle is re-weighted based on the probability of 
returning for a subsequent cycle given the covariate distribution in the cycle.14 The 
weights are then multiplied across the cycles to create one weight per individual. This is 
different from survival analysis because the weighting is based on individual cycle 
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covariates, and not the average cohort probability. In this pseudo-population, IPCW 
removes the relationship between the exposure (or covariates) and being censored, 
thereby removing the selection bias.11 The IPCW estimate is the cumulative incidence of 
live birth if a woman achieves a live birth or completes up to six IVF cycles. 
The aims of this study are to obtain a more valid estimate of the clinically-
relevant measure of IVF success, cumulative incidence of live birth, using IPCW 
estimation to account for the variability in the probability of IVF success of those who 
drop out of treatment, thereby addressing some of the methodological limitations of prior 
methods, and to compare the cumulative incidence of live birth using multiple methods. 
 
4.2 METHODS 
4.2.1 Study population 
We identified all IVF cycles performed at Boston IVF, from January 1, 1995 
through December 31, 2014.  Women were included if their first known fresh autologous 
cycle was performed at Boston IVF, and all cycles, fresh and frozen, were included for 
each woman until the first live birth or up to six completed cycles, whichever came first. 
 
4.2.2 Outcome 
The outcome was live birth and we measured the cumulative incidence of live 
birth across multiple cycles of IVF. Our definition of cumulative incidence of live birth 
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differs from the SART definition; in our definition, each cycle is treated as a separate 
observation. 
 
4.2.3 Statistical analysis 
We used several analytic techniques to calculate the cumulative incidence of live 
birth. First, we used a “per cycle” technique. We report the cumulative incidence of live 
birth at each cycle, and the cumulative incidence of live birth with all cycles in the 
denominator. Second, we used a traditional Kaplan-Meier survival analysis, “optimistic” 
approach, where women were censored if they did not have a live birth and did not return 
for a subsequent IVF cycle. Women who did not achieve a live birth after six cycles were 
censored because Massachusetts mandates that insurance companies cover up to six 
cycles. Third, in order to mirror Malizia et al.,8 we also generated a “conservative” 
estimate by not censoring women before the end of six IVF cycles.  
Finally, we implemented IPCW, with censoring defined in the same way as for a 
traditional Kaplan-Meier approach. The dataset was structured to contain one observation 
for each IVF treatment cycle. A variable was created to indicate whether the woman was 
censored after the conclusion of each cycle. Women were censored if they did not have a 
live birth and did not continue to the next treatment cycle. Next, the denominator of the 
censoring weight was calculated. A pooled logistic regression model was used to 
determine the probability of continuing to the next cycle by using censoring as the 
dependent variable (modeling continuation or the probability or remaining uncensored) 
and all time varying and non-time varying covariates as the independent variables. The 
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time-varying covariates chosen for the weights were age at the start of the cycle, 
pregnancy loss in the cycle, gravidity at the start of the cycle, procedure type (i.e. 
whether a fresh or frozen embryo was used for implantation), primary infertility 
diagnosis, number of mature oocytes, number of embryos transferred, cancelled cycle, 
donor vs. autologous cycle, and the year of the cycle. C-statistics were used to determine 
the predictability of the pooled logistic model for the denominator. The probability was 
calculated for each treatment cycle and then multiplied across each individual to create 
the denominator portion of the final weight. This weight is known as the unstabilized 
IPCW. Unstabilized weights may have extreme observations due to individuals with a 
rare combination of covariates (and therefore a large weight) that can influence the 
results.13,15 Therefore, a numerator is added to the weights that contains non-time varying 
covariates only, creating a stabilized weight.13–15 The process for building the numerator 
was identical to the process for building the denominator, except that only non-time 
varying covariates were used and multiplied across each individual for the numerator 
weight. In this dataset, the only non-time-varying covariate available was parity. 
Stabilized IPCWs should have a mean of one.13 Finally, in order to further ensure that 
one individual with a rare combination of covariates (and therefore a large weight) did 
not influence the final result, the final inverse weights were truncated at the 99th 
percentile.13 
Assumptions required for IPCW to appropriately remove selection bias include 
consistency, exchangeability, positivity, and no misspecification of the model used to 
estimate the weights. Consistency means that the individual’s potential outcome given 
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their covariate history is the observed outcome.13 In the case of censoring, since the 
model is meant to be predictive and not causal, this concept does not easily translate. 
Exchangeability, otherwise known as the assumption of no unmeasured confounding,13 is 
not testable; however, we did test several censoring models in an attempt to meet this 
assumption. Positivity assumes that there are censored and uncensored values at every 
level of the confounders, thereby guaranteeing no structural zeros in the dataset. Finally, 
although not testable, several different models were explored in an attempt to ensure a 
well-specified model for the weights. The IPCW was used in the final Kaplan-Meier 
model.16 
For the “optimistic,” “conservative,” and IPCW approaches, cumulative incidence 
of live birth was calculated by subtracting the survival probability from 1. Graphs were 
constructed using the cumulative incidence of live birth. A woman’s age is a very strong 
predictor of IVF success. Therefore, a stratified analysis was conducted using each 
approach. Age at the start of each cycle was used for the “per cycle” approach and age at 
the start of the first cycle was used for the “optimistic,” “conservative,” and IPCW 
approaches. Age categories were based on the Society for Assisted Reproductive 
Technology standards (<30, 30<35, 35-<38, 38-<41, 41-42, >42 years), with a category 
added for those aged <30 years.9 
 
4.3 RESULTS 
We included 20,010 women who contributed 47,727 IVF cycles and 10,319 live 
births. Demographic characteristics for these women at the start of their first cycle are 
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presented in Table 4.1. On average, women were 35.7 ± 4.6 years of age, and the 
majority were nulliparous (61.4%). More than one-third of the women (36.8%) had an 
unknown cause for infertility. The majority of women (86.9%) had private insurance. At 
the end of the first cycle, 18.7% of women eligible for the next cycle did not return for 
cycle 2. This proportion increased with each cycle and 34.6% of those eligible to return 
for cycle 6 did not. The proportion of eligible women returning for subsequent cycles 
decreased with increasing age (Table 4.2). 
The “per cycle” success of IVF decreased with each cycle, from 23.7% for cycle 1 
to 17.9% for cycle 6, but overall, was 21.6% (Table 4.2). Among women less than 30 
years of age at the start of the cycle, the “per cycle” success was higher, ranging from 
31.1% for cycle 1 to 21.7% for cycle 6, and 29.8% overall. In contrast, among women 
over 42 years of age, the “per cycle” success was lower, 3.3% for cycle 1, 17.3% for 
cycle 6, and 7.7% overall.  
Cumulative incidence of live birth and cumulative incidence curves calculated 
from the Kaplan-Meier approach are presented in Table 4.3 and Figure 4.1 for both the 
“optimistic” approach and “conservative” approach. From these data, the cumulative 
incidence of live birth after six IVF cycles was 73.9% (72.8-74.9%) using the 
“optimistic” definition of censoring. When using the “conservative” approach, the 
cumulative incidence of live birth was 51.6% (95% CI 50.9-52.3%). Women less than 30 
years of age had the highest cumulative incidence of live birth for both the “optimistic” 
estimate (85.9%) and “conservative” estimate (66.3%) compared with women who were 
over 42 years of age at their first cycle (44.9% and 16.5%, respectively).  
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The model for the numerator of the weights included parity, because this was the 
only available covariate that did not vary across cycles. The c-statistic for the 
denominator model, mean of the calculated weights, and minimum and maximum of 
unstabilized and stabilized weights are presented in Table 4.4. The final model for the 
denominator had a c-statistic of 0.667 and mean stabilized weight of 0.99. The weights 
were truncated at the 99th percentile for a final mean weight of 0.98. Several of the 
covariates were assessed across the cycles to ensure the model met the positivity 
assumption (Table 4.5). 
After incorporating the IPCW into the Kaplan-Meier model, cumulative incidence 
of live birth after six IVF cycles was 69.1% (95% CI: 67.9-70.4%) (Table 4.3 and Figure 
4.1) when adjusting for the stabilized weights. The IPCW age-stratified cumulative 
incidence of live birth percentages were similar to the “optimistic” approach for all age 
groups. For women <35 years of age, the cumulative incidence of live birth calculated by 
the IPCW was slightly higher than the “optimistic” approach, but for women 41 year of 
age or older, the “optimistic” cumulative incidence of live birth was slightly higher. The 
“conservative” estimate was lower for all age groups.  
 
4.4 DISCUSSION 
While several different approaches to quantifying IVF success have been used, 
many of them have methodological challenges.2,8–10 The SART cumulative incidence of 
live birth does not account for multiple embryo retrieval cycles for each woman, and does 
not provide information about the number of all cycles needed to achieve a live birth. 
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While using survival analysis does overcome most of these issues, it introduces a new 
potential challenge by violating the uninformative censoring assumption. The proposed 
solution is the use of IPCW.  
Our results for the “optimistic” and “conservative” approaches were very similar 
to Malizia et al.,8 who used the same clinic data based on a shorter time period (2000-
2005). The IPCW estimated cumulative incidence of live birth for the whole cohort fell in 
between the “conservative” and “optimistic” approach, as expected, although was very 
similar to the “optimistic” approach. When stratified by the woman’s age at the start of 
cycle 1, the “optimistic” Kaplan-Meier and IPCW approach remained similar.  
This method has several limitations. First, although we were able to minimize 
selection bias due to informative censoring, we were not able to completely eliminate it. 
Residual bias may remain. In addition, our c-statistic was 0.667, indicating that our 
model was not strongly predictive of remaining uncensored. Inclusion in the model of 
additional covariates, such as clinical predictors of fertility, non-varying covariates, and 
information related to treatment decision making may have improved predictability of the 
estimates. 
IPCW has several strengths, notably the ability to decrease selection bias due to 
loss to follow-up. More predictive models would be able to better address potential bias. 
In addition, this approach can be tailored to different study questions and used in 
marginal structural models to estimate a relationship between an exposure and outcome 
where the effect of selection bias may be greater.  
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4.5 CONCLUSION 
Currently, there is limited information about why couples leave IVF treatment and 
further research in this area is needed. Understanding the reasons for treatment drop out 
and loss to follow up is important and this information may be included in future IPCW 
models for better prediction and more accurate estimates. In addition, validation of this 
method is needed in other datasets. Nevertheless, using IPCW can provide clinicians, 
patients, and stakeholders with a more accurate estimate of treatment success for 
counseling and decision-making around IVF.  	  
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4.6 TABLES 
Table 4.1: Baseline characteristics of in vitro fertilization (IVF) cohort at the 
beginning of cycle 1, n=20,010  
Characteristics N=20,010 
Age (years)  35.7 ± 4.6 
Gravidity  
0 9,568 (47.8) 
1 4,882 (24.4) 
2 2,589 (12.9) 
3+ 2,451 (12.2) 
Unknown 520 (2.6) 
Parity  
0 12,285 (61.4) 
1 3,982 (19.9) 
2+ 1,090 (5.4) 
Unknown 2,653 (13.3) 
Primary diagnosis/reason for IVF  
Female factor infertility  
Ovarian dysfunction 1,463 (7.3) 
Diminished ovarian reserve 872 (4.4) 
Endometriosis 1,300 (6.5) 
Polycystic ovarian syndrome 345 (1.7) 
Tubal factor infertility 2,876 (14.4) 
Uterine factor infertility 446 (2.2) 
Other 701 (3.5) 
Male factor infertility 4,409 (22.0) 
Unknown 7,359 (36.8) 
Pre-implantation genetic screening 239 (1.2) 
Insurance status  
Insured 17,381 (86.9) 
Self-pay 1,550 (7.7) 
Unknown 1,079 (5.4) 
Data presented as mean ± standard deviation or n (%) 
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Table 4.2: “Per cycle” in vitro fertilization (IVF) success and cycle distribution up to 
six cycles, stratified by age at the start of each cycle 
Cycle number Number in 
cohort 
Live birth 
N (%) 
Eligible to 
return for next 
cycle 
Number (%) who 
did not return for 
next cycle 
1 20,010 4,744 (23.7) 15,271 2,858 (18.7) 
2 12,419 2,599 (20.9) 9,820 2,370 (24.1) 
3 7,450 1,536 (20.6) 5,914 1,693 (28.6) 
4 4,221 776 (18.4) 3,445 1,079 (31.3) 
5 2,366 438 (18.5) 1,928 667 (34.6) 
6 1,261 226 (17.9) -  
Total cycles 47,727 10,319 (21.6) -  
Total women 20,010 10,319 (51.6) -  
Age < 30     
1 2,281 710 (31.1) 1,571 459 (29.2) 
2 1,112 314 (28.2) 798 220 (27.6) 
3 578 172 (29.8) 406 143 (35.2) 
4 263 67 (25.5) 196 71 (36.2) 
5 125 38 (30.4) 87 41 (47.1) 
6 46 10 (21.7) -  
Total cycles 4,405 1,311 (29.8) -  
Total women 2,281 1,311 (57.4) -  
Age 30-<35     
1 6,570 2,018 (30.7) 4,552 814 (17.9) 
2 3,738 972 (26.0) 2,766 625 (22.6) 
3 2,141 561 (26.2) 1,580 434 (27.5) 
4 1,146 242 (21.1) 904 313 (34.6) 
5 591 147 (24.9) 444 167 (37.6) 
6 277 70 (25.3) -  
Total cycles 14,463 4,010 (27.7) -  
Total women 6,570 4,010 (61.0) -  
Age 35-<38     
1 4,410 1,113 (25.2) 3,297 511 (15.5) 
2 2,786 669 (24.0) 2,117 486 (23.0) 
3 1,631 338 (20.7) 1,293 374 (28.9) 
4 919 191 (20.8) 728 208 (28.6) 
5 520 97 (18.7) 423 135 (31.9) 
6 288 53 (18.4) -  
Total cycles 10,554 2,461 (23.3) -  
Total women 4,410 2,461 (54.9) -  
Age 38-<41     
1 3,990 713 (17.9) 3,277 628 (19.2) 
2 2,649 438 (16.5) 2,211 568 (25.7) 
3 1,643 292 (17.8) 1,351 354 (26.2) 
4 997 154 (15.4) 843 255 (30.2) 
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5 588 94 (16.0) 494 170 (34.4) 
6 324 44 (13.6) -  
Total cycles 10,191 1,735 (17.0) -  
Total women 3,990 1,735 (42.0) -  
Age 41-42     
1 1,861 160 (8.6) 1,701 304 (17.9) 
2 1,397 154 (11.0) 1,243 304 (24.5) 
3 939 118 (12.6) 821 376 (33.6) 
4 545 88 (16.1) 457 140 (30.6) 
5 317 36 (11.4) 281 105 (37.4) 
6 176 23 (13.1) -  
Total cycles 5,235 579 (11.1) -  
Total women 1,861 579 (27.3) -  
Age >42     
1 898 30 (3.3) 868 131 (15.1) 
2 737 52 (7.1) 685 167 (24.4) 
3 518 55 (10.6) 463 112 (24.2) 
4 351 34 (9.7) 317 92 (29.0) 
5 225 26 (11.6) 200 50 (25.0) 
6 150 26 (17.3) -  
Total cycles 2,879 223 (7.7) -  
Total women 898 223 (15.9) -  
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Table 4.3: Comparison of cumulative incidence of live birth by statistical approach, 
stratified by woman’s age (years) at the start of cycle 1 
 Kaplan-Meier 
(“Optimistic”) 
approach 
No censoring 
(“Conservative”) 
approach 
IPCW approach 
Whole cohort 73.9% (72.8-74.9) 51.6% (50.9-52.3) 69.1% (67.9-70.4) 
Age <30 85.9% (83.4-88.1) 66.3% (64.2-68.4) 91.0% (88.6-93.0) 
Age 30-<35 82.0% (80.6-83.4) 65.1% (63.9-66.3) 85.4% (83.9-86.8) 
Age 35-<38 73.6% (71.6-75.6) 56.5% (55.1-58.0) 75.7% (73.5-77.8) 
Age 38-<41 64.4% (61.9-66.9) 42.9% (41.4-44.5) 62.0% (59.3-64.7) 
Age 41-42 52.3% (47.4-57.3) 27.2% (25.4-29.1) 48.2% (43.9-52.7) 
Age >42  44.9% (36.2-54.7) 16.5% (14.7-18.6) 37.6% (32.2-43.6) 
Data presented as cumulative incidence (95% confidence interval) 	  
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Table 4.4: Model building for inverse probability-of-censoring weights 
Model Weight mean ± 
standard deviation 
Weight minimum/ 
maximum 
C-statistic* 
Parity at baseline, age    
Unstabilized 1.79 ± 0.96 1.05/19.8 0.610 
Stabilized** 1.02 ± 0.20 0.38/4.66  
Parity at baseline, age, number of 
mature oocytes 
   
Unstabilized 1.69 ± 0.90 1.00/20.21 0.626 
Stabilized** 0.97 ± 0.23 0.26/3.79  
Parity at baseline, age, prior 
cancelled cycle 
   
Unstabilized 1.82 ± 1.05 1.05/26.84 0.628 
Stabilized** 1.04 ± 0.25 0.38/6.98  
Parity at baseline, age, insurance    
Unstabilized 1.80 ± 1.25 1.05/71.13 0.622 
Stabilized** 1.03 ± 0.30 0.34/15.31  
Parity at baseline, age, fresh vs. 
frozen cycle 
   
Unstabilized 1.79 ± 1.01 1.05/27.36 0.616 
Stabilized** 1.02 ± 0.21 0.40/5.71  
Parity at baseline, age, infertility 
diagnosis 
   
Unstabilized 1.79 ± 1.01 1.06/28.16 0.613 
Stabilized** 1.02 ± 0.22 0.37/5.00  
Parity at baseline, age, cycle year    
Unstabilized 1.79 ± 0.96 1.06/19.83 0.610 
Stabilized** 1.02 ± 0.20 0.38/4.64  
Parity at baseline, age, gravidity    
Unstabilized 1.80 ± 1.03 1.05/27.20 0.616 
Stabilized** 1.02 ± 0.23 0.37/6.89  
Parity at baseline, age, prior 
outcome loss 
   
Unstabilized  1.79 ± 0.97 1.06/21.24 0.611 
Stabilized** 1.02 ± 0.20 0.38/5.38  
Parity at baseline, age, number of 
embryos transferred 
   
Unstabilized  1.81 ± 1.01 1.05/25.19 0.618 
Stabilized** 1.03 ± 0.23 0.36/5.27  
Parity at baseline, age, donor vs. 
autologous 
   
Unstabilized 1.79 ± 0.96 1.06/18.75 0.610 
Stabilized** 1.02 ± 0.20 0.37/4.46  
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Full model: parity at baseline, 
age, number of mature oocytes, 
prior cancelled cycle, 
insurance, fresh vs. frozen 
cycles, gravidity, prior outcome 
loss, infertility diagnosis, cycle 
year, number of embryos 
transferred, donor vs. 
autologous 
   
Unstabilized 1.76 ± 1.62 1.00/91.81 0.667 
Stabilized** 0.99 ± 0.46 0.25/32.05  
* C-statistic calculated from the pooled logistic denominator model 
** Stabilized models include a numerator adjusting for parity at baseline 	  
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Table 4.5: Comparing censored with uncensored women to test positivity 
assumption of IPCW 
 Censored 
(n=9,691) 
Continued 
(n=38,036) 
Age (years) 37.6 ± 4.8 35.9 ± 4.7 
Parity   
0 5,647 (58.3) 24,106 (63.4) 
1 2,067 (21.3) 7,085 (18.6) 
2+ 639 (6.6) 1,642 (4.3) 
Missing/unknown 1,338 (13.8) 5,203 (13.7) 
Gravidity   
0 3,316 (34.2) 16,388 (43.1) 
1 2,503 (25.8) 10,157 (26.7) 
2 1,711 (17.7) 5,459 (14.4) 
3+ 1,832 (18.9) 4,962 (13.0) 
Missing/unknown 329 (3.4) 1,070 (2.8) 
Insurance   
Insured 7,931 (81.8) 33.754 (88.7) 
Self-pay 1,046 (10.8) 1,999 (5.3) 
Unknown 714 (7.4) 2,283 (6.0) 
Primary diagnosis/reason for IVF   
Female factor infertility   
Ovarian dysfunction 620 (6.4) 2,726 (7.2) 
Diminished ovarian reserve 813 (8.4) 2,050 (5.4) 
Endometriosis 531 (5.5) 2,272 (6.0) 
Poly cystic ovarian syndrome 126 (1.3) 728 (1.9) 
Tubal factor infertility 1,347 (13.9) 5,033 (13.2) 
Uterine factor infertility 254 (2.6) 786 (2.1) 
Other 462 (4.8) 1,215 (3.2) 
Male factor infertility 1,856 (19.2) 8,370 (22.0) 
Pre-implantation genetic screening 170 (1.8) 523 (1.4) 
Unknown 3,512 (36.2) 14,333 (37.7) 
Data presented as mean ± standard deviation or n (%) 	  
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4.7 FIGURES 
Figure 4.1: Comparison of Kaplan-Meier curve (“Optimistic” approach), No 
censoring (“Conservative” approach) and IPCW approach to calculate cumulative 
incidence of live birth 
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5.0 CONCLUSIONS 
The use of in vitro fertilization (IVF) is increasing in the United States and it is 
important to understand the risks associated. Ischemic placental disease (IPD) is a 
potentially serious set of adverse outcomes that are believed to share a biological 
mechanism. While IVF has been shown to increase the risk of preeclampsia,1–9 small for 
gestational age (SGA) infants,6,10–12 and placental abruption,2,4,5 none of these have 
assessed the risk of IPD as a combined outcome in the IVF population. There are several 
potential mechanisms proposed for the increased risk of IPD in IVF pregnancies, 
including a heightened maternal immune response to the fetus specifically in donor IVF, 
underlying infertility, and prematurely elevated serum progesterone during IVF 
treatment.1,7,13–16 In this dissertation, we have attempted to evaluate the association 
between donor IVF and the risk of IPD, and the association between premature elevated 
serum progesterone and the risk of IPD. 
Analytic methods to quantify IVF success have not kept pace with the 
technological advances that have improved the success of IVF.17–20 In this dissertation, 
we compared several of the methods used to calculate cumulative incidence of live birth, 
the most widely accepted clinical measure of IVF success, and propose the use of inverse 
probability-of-censoring weighting (IPCW) to address the issue of treatment dropout. 
In our first study, we showed that pregnancies conceived via donor IVF or 
autologous IVF had a higher IPD risk than non-IVF pregnancies; furthermore, these risks 
were consistently stronger for donor than autologous IVF. This was consistent with our 
hypothesis and lends support to the immunological theory; however, this theory does not 
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explain the increased risk of IPD in the autologous IVF group. In addition, the estimates 
for each component of IPD were different, which is also not entirely explained by a 
single mechanism. The increased risk of IPD in the autologous IVF group may be due to 
either the underlying infertility or IVF treatment, although our study was not designed to 
address this. Our second study assessing the role of serum progesterone on the day of 
human chorionic gonadotropin (hCG) administration showed an association between 
elevated progesterone and IPD, although our sample size was small and the results were 
imprecise. We did not see a large range in progesterone levels, particularly in the upper 
range of the distribution. Elevated progesterone has been associated with a decrease in 
live birth rates; thus, it is possible that providers cancel IVF cycles out of concern for a 
failed cycle. 
Finally, in our third study, we used IPCW to calculate the cumulative incidence of 
live birth and account for women who left treatment prior to achieving a live birth or six 
IVF cycles. We found that the overall cumulative incidence of live birth was lower when 
using IPCW compared with a traditional Kaplan-Meier approach; however, the estimates 
were similar. Overall the traditional Kaplan-Meier and IPCW approaches were similar 
when stratified by age groups. This was not the case in women less than 35 years of age, 
where the traditional Kaplan-Meier approach underestimated the IPCW approach. 
This dissertation had several limitations. The first is the use of electronic medical 
records, which may lead to misclassification of the exposure, outcome and covariates. In 
addition, the use of electronic records limits the availability of information on covariates. 
For our first study, we were unable to identify all women who underwent IVF in our non-
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IVF group. We are confident in our IVF groups and also would expect that the 
misclassification is non-differential with respect to the outcome. We did not find a 
difference in the effect estimates when we corrected for the exposure misclassification 
using probabilistic bias analysis.21 In addition, our use of ICD9 codes to identify 
preeclampsia and placental abruption caused outcome misclassification due to over and 
under diagnosis of IPD. We were able to conduct a medical record review to confirm 
approximately half of the ICD9 codes; however, we were unable to confirm any ICD9 
codes prior to July 1, 2008. We also were not able to review the records of women 
without an ICD9 code for preeclampsia and placental abruption; thus, it is possible that 
women with these conditions were missed. Given preeclampsia and placental abruption 
are serious medical conditions, we likely have high specificity, increasing our confidence 
in the results. Among the records reviewed, the ICD9 code has high positive predictive 
value, suggesting the effect of misclassification is small. Furthermore, we would not 
expect the misclassification to differ by IVF status given the severity of IPD. A bias 
analysis conducted to evaluate the effect of outcome misclassification showed corrected 
estimates that were stronger than the observed estimates. We carried out several 
sensitivity analyses to address the limitations of our data, and our results were robust. Our 
use of data from a single institution may limit the generalizability of our results. 
However, the demographics and outcome prevalence at our institution was as expected; 
therefore, the cohort was likely representative of the general population.  
Our study assessing the effect of progesterone on IPD was a subset of the IVF 
population in our first study, and we had similar limitations in the two studies. In 
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addition, since this was a subset of the population, our study sample was small. We also 
were unable to conduct many sensitivity analyses to address some of the limitations.    
It is important to note that while IPD has been found to have a common biological 
etiology, some studies suggest that SGA may be a heterogeneous outcome with multiple 
causes, including, but not limited to placental insufficiency.22–25 Among the SGA infants 
in our first two studies, some of the causes of SGA may have been unrelated to placental 
findings.    
In the last study, the main limitation was our limited information on the reasons 
that women dropped out of treatment, as well as information related to the time between 
each cycle. In building our weights for the IPCW analysis, the c-statistic measuring the 
predictive ability of the model was only moderately strong.  
With the increase in the use of IVF, there will be a steady increase in the 
population of women and their children affected by potentially serious adverse events. 
Despite the limitations, this dissertation provides important insight into the relationship 
between IVF and IPD. The use of IPD as a composite variable allowed us to examine the 
effects of IVF on a group of biologically linked conditions, shedding light on a biological 
mechanism, which may be useful for future studies. Future studies addressing the 
immune response in pregnancy, specifically with respect to donor IVF, can examine 
biomarkers in pregnancies affected by all three of these conditions. Understanding this 
mechanism can lead to potential treatments, or methods of prevention. The first study 
was large and we were able to conduct multiple sensitivity analyses. We could also assess 
the relationship between donor and autologous IVF and the individual components of 
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IPD. While treatment and policy decisions should not be made based on a single study, 
the increased risk of the components of IPD seen in this study is in line with increasing 
evidence in the literature.1–12 Currently, the United States Preventative Task Force does 
not include IVF on the list of risk factors for preeclampsia and does not recommend the 
use of aspirin as prophylaxis;26 however, this may warrant reconsideration. The second 
study was one of the first to examine the effect of serum progesterone on IPD. However, 
due to our imprecise results, further research is needed in order to determine whether 
there is a true association between progesterone levels on the day of hCG administration 
and IPD. At this time, our study alone, in the context of limited literature, is not sufficient 
to make any recommendations or changes. Finally, we were able to evaluate a method of 
calculating cumulative incidence of live birth that may decrease the effect of selection 
bias. IPCW, in conjunction with inverse probability-of-treatment weights, also can be 
used to calculate the associations between an exposure and cumulative incidence of live 
birth, which is useful for future studies. Consensus needs to be reached on the best way to 
calculate cumulative incidence of live birth to allow clinicians and patients to make well-
informed decisions about their treatment. Undergoing IVF treatment can take a large 
financial can psychological toll on women and couples27 and providing them with 
accurate information about the risks and probabilities of success is critical.  
IVF use among infertile couples has increased steadily over the last few decades. 
Although its use has been associated with higher pregnancy rates, there are risks 
associated with IVF, such as IPD. Future studies confirming our results are needed, and 
should address the underlying biological mechanisms.	  
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